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Multidrug resistance protein 4 (MRP4/ABCC4) is a member of the ATP-binding 
cassette transporter superfamily. MRP proteins contribute to the resistance to a variety 
of chemotheraputic agents and the transport of structurally diverse conjugated organic 
anions, including glutathione-S-conjugates. Previous studies had shown that MRP4 
can mediate the resistance to purine analogs, such as anti-HIV drug 6-thioguanine. In 
this study, MRP4 was also observed to confer the resistance to anti-cancer drug 2’,2’-
difluorodeoxycytidine, a deoxycytidine analog. 
 
MRP1, MRP2 and MRP3 are all able to facilitate the efflux of glutathione-S-
conjugates, whereas it is unclear if MRP4 can also perform this transport function 
because of the differences in the membrane topology and drug resistance profiles 
between MRP4, MRP5 and the first three members of MRP family. MRP4 and MRP5 
are postulated to have only two transmembrane domains and two ATP-binding 
domains whereas the other members contain an extra N-terminal domain. Using cells 
stably overexpressing MRP4, this study shows that MRP4 can facilitate the efflux of 
the glutathione conjugate, bimane-glutathione. Bimane-glutathione efflux increased 
with time and > 85% of the conjugate was exported after 15 minutes. This transport 
was abolished in the presence of 2.5µM carbonylcyanide m-chlorophenylhydrasone, 
an uncoupler of oxidative phosphorylation. Inhibition was also observed with known 
inhibitors of MRP transporters including benzbromarone, verapamil and 
indomethacin. In addition, 100µM methotrexate, an MRP4 substrate or 100µM 6-
thioguanine, a compound whose monophosphate metabolite is an MRP4 substrate, 
reduced efflux by >40%. A concentration dependent inhibition of bimane-glutathione 
efflux was observed with 1,chloro-2,4-dinitrobenzene which is metabolized 
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intracellularly to the glutathione conjugate, 2,4-dinitrophenyl-glutathione. The 
determination that MRP4 can mediate the transport of glucuronide and glutathione 
conjugates indicates that MRP4 may play a role in the cellular extrusion of Phase II 
detoxification metabolites. 
 
To gain insight into the role of key amino acid residues of MRP4 protein for transport 
organic anions and resistance to chemotherapeutic compounds, we replaced two 
highly conserved charged amino acids Glu103, Arg362 and an aromatic residue Trp995 
in the transmembrane domain of MRP4 with conserved or non-conserved substitution. 
Site-directed mutagenesis was performed at these amino acid residues. All mutant 
clones were transfected into human Hep G2 cells and the localization and the 
expression levels of mutant MRP4 were comparable to that of wild-type MRP4. Our 
finding shows that all mutants can affect the transport activity as well as the drug 
resistance profiles of MRP4. Both conserved (E103D) and non-conserved (E103N, 
R362L) substitution of the two charged amino acids lost their ability to confer 
resistance to purine analogues 6-TG and gemcitabine and to transport of glutathione-
S-conjugates (bimane-GS). For aromatic amino acid Trp995 mutant, the drug 
resistance to 6-TG and transporter activity of bimane-GS was absent for the non-
conserved substitution. For the conserved mutation of Trp995 to Phe995, there was little 
effect on the resistance profile but this mutation greatly reduced the ability to transort 
bimane-GS. In brief, our present study indicates that the highly conserved charged 
amino acids Glu103, Arg362 and the aromatic residue Trp995 in the transmembrane 
domains of MRP4 are involved in determination of substrate specificity of MRP4-
mediated transport and drug resistance. 
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1.  Introduction 
1.1.  ABC Superfamily 
 
Adenosine triphosphate (ATP) binding cassette (ABC) proteins form one of the 
largest and most widespread protein superfamilies and its members are responsible for 
the active transport of a wide variety of compounds across biological membranes 
(Klein et al., 1999). 
 
As membrane transporters, the typical eukaryotic ABC protein contains four domains, 
two of which are hydrophobic, polytopic transmembrane domains (TMDs), also 
called membrane spanning domains (MSDs), and the other two are hydrophilic, 
cytosolic nucleotide binding domains (NBDs). They are organized in pairs (TMD-
NBD or NBD-TMD) and expressed either as one continuous unit or two separate 
polypeptides (Decottignies and Goffeau, 1997; Hipfner et al., 1999). 
 
Most ABC proteins are membrane transporters translocating various substrates to 
various compartments. Four types of transporters can be found on the cell membrane: 
ion channel, passive transporter, primary active transporter and secondary active 
transporter. ABC proteins belong to the primary active transporter category (Figure 
1.1). In most ABC transporters, the binding and subsequent hydrolysis of ATP at their 
NBDs is believed to provide energy for the movement of substrates across the 
membrane. The substrates include phospholipids, ions, peptides, steroids, amino 









ABCC1 ABCC2 ABCC3 ABCC4 ABCC5 ABCC6 ABCC7 ABCC8 ABCC9 ABCC10 ABCC11 ABCC12 ABCC13

















Analysis of the human ABC protein sequences revealed distinct subfamilies. This 
family is divided into four larger subfamilies – MRP/CFTR (to-date: thirteen 
members), MDR/TAP (eleven members), ALD (four members) and ABC1 (twelve 
members) – and three smaller groups – White (six members), GCN20 (three members) 
and one ‘single member’ subgroup OABP (Table 1.1). A large number of the known 
ABC proteins are active pumps. There are several exceptions, such as the human 
GCN20 homolog, ABC50. This dimeric ABC without TMDs is most probably not a 
transporter at all (Borst et al., 1999; Cole and Deeley, 1998; Hipfner et al., 1999; 















Subfamily name Alias Nomenclature 
ABC1, TGD HDLDT1 ABCA1 
ABC2 ABCA2 
ABC3, ABC-C EST111653 ABCA3 










Pgp1 MDR1 PGY1 ABCB1 
ABCB2, TAP1, PSF1, RING4, 
D6S114E 
TAP1 
ABCB3, TAP2, PSF2, RING11, 
D6S217E 
TAP2 
MDR2/3 PFIC-3 PGY3 ABCB4 
EST422562 ABCB5 
EST45597 umat Hs. 107911 ABCB6 
EST140535 Atm1p ABC7 ABCB7 
EST328128, M-ABC1 ABCB8 
EST20237 ABCB9 
EST20237 ABCB10 
M-ABC2, MABC2 ABCB10P 
MDR/TAP 
SPGP PFIC-2 BSEP PGY4 ABCB11 
MRP1 MRP, GS-X ABCC1 
MRP2 cMOAT cMRP  ABCC2 
MRP3 cMOAT2 EST90757 MLP2 
MOAT-D 
ABCC3 
MRP4 EST170205 MOAT-B ABCC4 
MRP5 SMRP EST277145 MOAT-C ABCC5 
MRP6 EST349056 MLP1 ARA  ABCC6 
CF MRP7 ABCC7  CFTR 














Subfamily name Alias Nomenclature 





ALDL1 ALDR ALDRP ABCD2 
PXMP1, PXMP70 ABCD3 
ALD 
EST352188 PXMP1L, P70R, PMP69 ABCD4 
OABP RL1 RNS4I RNASELI OABP ABCE1 
ABC50 EST123147 ABCF1 
EST133090 Hs. 153612 ABCF2 
GCN20 
EST201864 ABCF3 
ABC8 White ABCG1 
MXR1, BRCP, ABCP, EST157481 ABCG2 





















1.2.  Multi-drug resistance and MDR1 protein 
 
The MDR/TAP subfamily contains eleven members, in which MDR1 is the most 
extensively studied for its role in multidrug resistance. 
 
Cancer cells selected for resistance against a natural product drug normally are also 
cross-resistant to a range of other drugs with very different chemical structures or 
cellular targets. This type of resistance is defined as multidrug resistance (MDR) and 
it is probably the most frequent form of resistance in cell lines exposed to natural 
product drugs in vitro. The best-defined form of MDR in human cells is due to the P-
glycoprotein (Pgp) encoded by the human MDR1 gene.  
 
The multidrug transporter/P-glycoprotein (MDR1 or Pgp1) was the first cloned 
human ABC protein (Roninson et al., 1986; Fojo et al., 1985). This protein is located 
on the apical (or luminal) surface of polarized epithelial cells. It is found at the 
pharmacological barrier of the body and present on the brush border membrane of 
intestinal cell, on the biliary canalicular membrane of hepatocytes, as well as on the 
luminal membrane in proximal tubules of kidney (Bosch et al., 1996). 
 
The MDR1 transporter can extrude a wide range of structurally unrelated hydrophobic 
toxic compounds.  On the basis of its localization and its ability of vectorial transport 
of a range of toxic molecules, it is suggestive that the physiological function of 
MDR1 is to protect cells against toxic compounds.   
 
MDR1 is also expressed in tumor cells. At some stage of treatment with natural 
product drugs, the expression level of MDP1 increased 50% in all human tumors. 
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Moreover, some tumors failure to response to therapy is clearly related to the increase 
in Pgp. Due to the active pumping mechanism, MDR1 can extrude a range of 
hydrophobic anticancer drugs from the cell against a concentration gradient. 
Therefore, increased Pgp activity in tumor cells can lower the concentration of 
cellular chemotherapeutic agents and, this results in anti-cancer drug resistance. 
 
However, numerous phase I and II clinical trials to inhibit the multidrug resistance 
mediated by MDR1 had been carried out and the results showed that only a few 
patients had positive responses. This lack of response in the initial trials indicated that 
MDR1 mediated multidrug resistance is not the only single factor in the therapeutic 
outcome in human malignancies (Bosch et al., 1996). Meanwhile, in vitro 
experimental study also showed that Pgp is not the only cause of MDR. Many cells 
selected for resistance do not contain increased levels of Pgp but nevertheless are 
resistant to a broad range of natural product drugs. Several of these cell lines contain 
raised levels of a second member of the ABC transporter proteins, the MDR-
associated protein (MRP), which was discovered by Cole et al. (Cole et al. 1992). 
 
The drug resistance phenotype of MRP protein overlaps with that of Pgp. It is 
associated with resistance to anthracyclines, etoposide, and vince alkaloids. However, 
MRP and Pgp do not result in exactly the same spectrum of drug resistance. MRP 
does not confer resistance to taxol, a clinically important agent that is part of the Pgp 
resistance profile. Also, multidrug resistance caused by Pgp is readily reversed by 





1.3.  MRP Family 
 
The MRP (ABCC) family entered the drug resistance scene in 1992 when multidrug 
resistant-associated protein gene 1 (MRP1) was cloned by Susan Cole et al. (Cole et 
al., 1992). To date, this subfamily is currently the largest in the human ABC family, 
consisting of thirteen members of which nine are MRP proteins.  
 
Subsequently to the identification of MRP1, MRP2 followed in 1996 (Buchler et al., 
1996) and the notion of an MRP family with five members was introduced at the 
Gosau meeting on ABC transporters in 1997 by Marcel Kool (Klein et al., 1999). 
MRP6 was cloned in 1998 (Kool et al., 1999b) and MRP7 was in 2001 (Hopper et al., 
2001). Recently the sequences of two more new human ABC transporters, MRP8 and 
MRP9, were described (Tammur et al., 2001). 
 
Other members of ABCC subfamily including the sulfonylurea receptors, SUR1 and 
SUR2, and CFTR (cystic fibrosis transmembrane conductance regulator) are of 
clinical, but not toxicological importance.  
 
MRPs are widely expressed in human tissues. MRP1 and MRP5 are ubiquitously 
expressed, but only a low abundance of their transcripts were detected in liver. MRP2, 
MRP3, and MRP6 are mainly expressed in liver, gut and kidney while MRP4 is 
highly expressed in prostate, testis, and ovary (Table 1.2). In polarized monolayer 
cells, MRP2 is routed to the apical membrane as MDR1, while MRP 1, -3, -4, and –5 




Table 1.2 The chromosomal localization of each MRP gene, the cellular localization 
and the tissue distribution of MRP proteins. 
 
Name Chromosome Amino acid Location Tissue 
MRP1 16p13.1 1531 Basolateral Ubiquitous 
MRP2 10q24 1545 Apical Liver, intestine, kidney, 
gut 
MRP3 17q22 1527 Basolateral Intestine, kidney, liver, 
adrenals, pancreas, gut 
MRP4 13q32 1325 Basolateral Prostate, lung, muscle, 
pancreas, testis, ovary, 
bladder, gallbladder 
MRP5 3q27 1437 Basolateral Ubiquitous 
MRP6 16p13.1 1503 Basolateral Kidney, liver 
MRP7 6p12-21 1492 ND Liver, kidney, heart, 
colon, brain, skin, 
pancreas, testis 
MRP8 16q12.1 1382 -- -- 
MRP9 16q12.1 1359 -- -- 
  
 
The membrane topology of MRP subfamily can be categorized into two types.  
MRP1-related proteins (MRP1, MRP2, MRP3 and MRP6) contain the characteristic 
third N–terminal membrane spanning domain (MSD1), which contains five 
transmembrane helices, while the smaller MRP-related proteins (MRP4, MRP5) have 
the more typical ABC four-domain structure that lacks this extension (Figure 1.2). 
 
Within the MRP family, homology is highest between MRP1, -2, -3 and –6 while the 
more distantly related MRP4 and MRP5 lacking MSD1/TMD0 share lower amino 



















Figure. 1.2. Two-dimensional membrane topology models for MRP1 and MRP5. 
MRP1 is characterized by the presence of an extra N-terminal domain (TMD0), which 
is absent in MDR4 or MRP5. Note that this figure presents highly schematic models 
only indicating the transmembrane segments, nucleotide binding domains (NBDs), 
and the location of carbohydrate (CHO) chains. In reality, the transmembrane 
segments probably come together in the membrane to form a kind of pore closed off 
at the exoplasmic phase (Borst et al., 2000). 
 
 
Table 1.3 MRP proteins sequence alignments (Klein et al.,1999; Belinsky et al.,1999 
and Hooper et al.,2001). 
 
 MRP1 MRP-2 MRP3 MRP4 MRP5 MRP6 
MRP2 49.8 
(66.0/73.1) 














































Note. Overall percent amino acid similarity is indicated in boldface. Percent identity 




MRP1, MRP2, and MRP3 bear a close structural resemblance, confer resistance to a 
variety of natural products as well as methotrexate, and have the facility for 
transporting glutathione-, glucuronide-, and sulfate-conjugates (Leslie et al., 2001b; 
Cole and Deeley, 2002). MRP1 is a ubiquitously expressed efflux pump for the 
products of phase II xenobiotic detoxification (Loe et al., 1998; Hipfner et al., 1999). 
The physiological function of MRP2, whose hereditary deficiency results in Dubin-
Johnson syndrome, is to facilitate the extruding of bilirubin glucuronide into the bile 
(Paulusma et al., 1999; Konig et al., 1999). MRP3 is distinguished by its capacity to 
transport the monoanionic bile constituent glycocholate, and may function as a 
basolateral back-up system for the detoxification of hepatocytes when the usual 
canalicular route is impaired by cholestatic conditions (Konig et al., 1999). MRP4 and 
MRP5 resemble each other more closely than they resemble MRP1-3. They confer 
resistance to purine and nucleotide analogs including those that are inherently anionic, 
such as the anti-AIDS drug 9-(2-phosphonylmethylethyl) adenine (PMEA), and 
phosphorylated anionic amphiphiles in the cell, such as 6-mercaptopurine (6-MP) 
(Schuetz et al., 1999; Lee et al., 2000; Wijnholds et al., 2000). Given their capacity 
for transporting cyclic nucleotides, MRP4 and MRP5 have also been implicated in 
cellular signaling (Chen et al., 2001; Lai et al., 2002). MRP6 was demonstrated as an 
active transporter of glutathione conjugates but not glucuronate conjugates and 
confers of low-level resistance to certain anticancer agents (Belinsky et al., 2002; Ilias 
et al., 2002). Hereditary deficiency of MRP6 results in pseudoxanthoma elasticum, a 
multisytem disorder affecting skin, eyes, and blood vessels (Bergen et al., 2000). 
MRP7 was recently demonstrated to catalyze the active transport of glutathione 




While MRP 1-9 are active pumps as most ABC proteins are, SUR1 and SUR2 are best 
described as intracellular ATP sensors that regulate the permeability of potassium 
channels, and CFTR is only the chloride channel that may regulate other channel 
proteins. The lung disease cystic fibrosis is caused by mutations in CFTR and 
persistent hyperinsulinemic hypoglycemia of infancy is caused by mutations in SUR1  
(Klein et al., 1999; Welsh and Smith, 1993; Bryan and Aguilar-Bryan, 1997). 
 
1.3.1.   The role of MRP in detoxification 
  
Metabolism of toxicants 
Lipophilic xenobiotics and endogeneous compounds often have to be metabolized 
before being eliminated from the cell.  The metabolism of these compounds can be 
grouped into either Phases I or Phase II reactions.  
 
Phase I metabolism results in the introduction of a functional polar group, such as a 
hydroxyl, carboxyl, amino or thio group. In Phase II, the Phase I metabolite 
undergoes a conjugation reaction with various endogenous substrates, such as sugars, 
amino acids, glutathione (GSH), sulfate and so on, forming exceedingly water soluble 
products that are readily excreted (Hodgson et al., 1997). 
 
The reaction that is catalyzed by glutathione-S-transferases is an important Phase II 
reaction. Glutathione-S-conjugates are anionic in nature and are transported out of 
cells through an ATP-dependant process. A key feature of MRP proteins is the ability 
to transport glutathione-S-conjugates. 
 
 25
GSH Related Transport 
The transport of some toxin and drugs by MRP proteins requires the presence of 
GSH. Glutathione (GSH), γ-Glu-Cys-Gly, is a tripeptide derived from glycine, 
glutamate as well as cysteine and is present in all cells at high levels. GSH has many 
important roles in the protection of cells from oxidative stress. It is responsible for the 
removing of toxic peroxides that form in the course of growth and metabolism under 
aerobic conditions. The ratio of reduced GSH to the oxidized form, glutathione 
disulphide (GSSG), is a reflection of cellular redox status. Maintenance of low 
cellular GSSG concentrations and high GSH level is important for cellular 
homeostasis. Some MRP proteins, MRP1 and MRP2, can transport both GSH and 
GSSG, and therefore are potentially important in maintaining cellular redox status. 
 
Another important function of GSH is to aid detoxification. A variety of electrophilic 
compounds, including anticancer drugs, such as chlorambucil and melphalan, can be 
conjugated to GSH by glutathione S-transferase (GST) and are then transported out of 
the cell by MRPs (Klein et al., 1999; Borst et al., 2000). 
 
The conjugation of xenobiotics, which have electrophilic substituents with GSH, is 
catalyzed by one of the various forms of GST. 
 
R-X + GSH Æ R-SG + HX 
 
This reaction is extremely important in toxicology because, by removing the reactive 
electrophilies, vital nucleophilic groups in macromolecules, such as proteins and 
nucleic acids, are protected. The resulting R-SG is further metabolized through a 
series of reactions and finally into mercapturic acids that can be excreted either in the 
bile or in the urine (Hodgson et al., 1997). 
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In other instances, GSH was not conjugated to compounds but co-transported with the 
drugs by MRP. In both cases, a constant supply of GSH is required (Figure 1.3).  
 
 
Figure. 1.3. Model showing interrelation between multidrug resistance-associated 
protein (MRP) and glutathione (GSH). MRP1 transports oxidized glutathione (GSSG) 
at a relatively high concentration. Reduced GSH is transported out of the cell with 
very low affinity. However, some xenobiotics, such as the flavone apigenin and the 
calcium channel blocker verapamil, can be conjugated to GSH by glutathione S-
transferase (GST) and then transported by MRP; others are co-transported with GSH. 
In both cases, drug transport is dependent on the continue supply of GSH (Borst et al., 
2000; Leslie et al., 2001a). 
 
Elimination of xenobiotics by MRPs 
MRP proteins are considered as an amphipathic anion transporter that can transport 
uncharged, anionic or mildly cationic anticancer agents. Considering the structurally 
diverse nature of substrates transported by MRP proteins, deciphering the mechanism 
is complex. The current efflux model is that MRP1 contain a bipartite or multipartite 
binding site. One side of the structure can bind to the hydrophobic or anionic 
conjugated compounds or similarly to the unconjugated substrates while the other to 
GSH. For unconjugated compounds, they are co-transported with free GSH rather 
than converted into anions inside the cells (Loe et al., 1996a; Borst et al., 1999). 
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1.3.2.   MRP1 
 
Multidrug resistance protein (MRP1) is the founding member of the ABCC subfamily 
and was first cloned from multidrug resistant human small cell lung cancer cell line 
(Cole et al., 1992).  
 
Overexpression of the 190 kDa MRP1 in tumor cell lines and transfected cells results 
in an ATP-dependant efflux of several natural product type drugs with free GSH. 
These drugs include anthracyclines, epipodophyllotoxins, vinca alkaloids. MRP1 can 
also transport folic acid analogues, such as methotrexate, and certain arsenic and 
antimonial centered oxyanions (Cole et al., 1994; Hooijberg et al., 1999; Loe et al., 
1998; Hipfner et al., 1999).  
 
In addition to its ability to confer drug resistance, MRP1 is a primary active lipophilic 
anion transporter capable of transporting glutathione conjugates, such as the 
inflammatory mediator leukotriene C4 (LTC4) and 2,4-dinitrophenyl-GS (DNP-GS), 
as well as glucuronate and sulfate conjugates, such as the estrogen, 17β-estradiol 17-
β-D-glucuronide (E217βG) and sulfated bile salts, such as sulfatolithocholate 
(Jedlitschky et al., 1994, 1996; Loe et al., 1996b). 
 
MRP1 also mediates transport of oxidized GSH, glutathione disulfide (GSSG), and 
thereby prevents the reaction of GSSG with cellular thiols (Leier et al., 1996). The 
transport of reduced GSH alone is difficult to detect. However, it has been reported 
that verapamil, a calcium channel blocker, can increase MRP1’s affinity for GSH and 
this ability to stimulate GSH transport is shared by several dithiane analogs of 
verapamil and several flavonoids (Loe et al., 2000; Leslie et al., 2001b). 
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The clinical importance and the functional characteristics of this transporter are the 
subject of many investigations. MRP1 plays an important role in the prevention of 
cells and organs destruction from toxic compounds including heavy metal oxyanions 
and environmental chemicals. Due to its wide distribution and localization to the 
basolateral membrane of epithelial cells, this transporter tends to pump its subtrates 
into the interstitial space rather than excreting them into bile, urine or gut.  
 
For instance, the high concentration of MRP1 in the basal membrane of Sertoli cells, 
which surround male germ cells, can protect them by pumping xenobiotics out of the 
testicular tubule. Another example is MRP1 in choroids plexus epithelium. Here 
MRP1 can facilitate the exchange of metabolites between blood and cerebrospinal 
fluid (CSF). The absence of MRP1 results in considerable accumulation of 
intravenously administered etoposide in the CSF (Borst et al., 1999). 
1.3.3.   MRP2 
 
Prior to the discovery of MRP1, biochemical and genetic studies had demonstrated 
the presence of an organic anion transporter in the canalicular membrane of 
hepatocytes. This transporter was originally known as the canalicular multispecific 
organic anion transporter (cMOAT), but it is now called MRP2 (Buchler et al., 1996).  
 
This member of the MRP family bears a close resemblance to MRP1 in terms of both 
structure and substrate selectivity and also confers resistance to a variety of natural 
product agents (anthracyclines, vinca alkaloids, etoposide) as well as camptothecins 
and methotrexate (Cui et al., 1999; Hooijberg et al., 1999). However, MRP2 is 
notable for its capacity to confer resistance to cisplatin, which is known to form toxic 
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GSH complex in the cell while MRP1 and -3 do not confer resistance to this 
compound (Breuninger et al., 1995; Cole et al., 1994).  
 
In addition, MRP2 has a markedly different expression pattern. In contrast to MRP1, 
MRP2 is primarily expressed in canalicular (apical) hepatocyte membranes, where it 
functions as a biliary glutathione conjugate and glucuronide conjugate transporter 
(Buchler et al., 1996; Paulusma et al., 1999).  
 
Mutations in MRP2 cause Dubin-Johnson syndrome (DJS), an inherited defect in the 
secretion of amphiphilic anionic conjugates, especially bilirubin glucuronide, from 
hepatocytes into bile (Konig et al., 1999).  
1.3.4.   MRP3 
 
According to the coding sequence that has been determined, MRP3 shares the highest 
degree of structural resemblance with MRP1 (58%). However, in contrast to MRP1, 
the known drug resistance profile of MRP3 is narrow and restricted to 
epipodophyllotoxins, vincristine, and methotrexate (Kool et al., 1999a; Zeng, et al., 
1999). Moreover, the affinity of MRP3 for MRP1 substrates, such as LTC4 and 
E217βG, is much lower than that of MRP1 except for DNP-GS. In addition, one of the 
most striking differences from MRP1 and MRP2 is the high activity of MRP3 towards 
the conjugated monoanionic bile glycocholate but not taurocholate (Jedlitschky et al., 
1996; Loe et al., 1996b; Leier et al., 1994). 
 
With regard to physiological function, MRP3 may function in cholestatic conditions 
to efflux organic anions from liver into blood. It was reported that the hepatic MRP3 
expression is markedly increased in patients with Dubin-Johnson syndrome (Konig et 
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al., 1999; Kool et al., 1999a). It has been suggested that MRP2 and MRP3 may be 
regulated in a coordinated fashion and that MRP3 may mediate the efflux of organic 
anions from liver into blood (Borst et al., 2000). 
 
In addition, a recent study of human term placental tissue showed that MRP1 and 
MRP3 are predominantly expressed in blood vessel endothelial cells (St.Pierre et al., 
2000). Thus they may serve to prevent or limit the entry of organic anions into fetal 
circulation and simultaneously to allow the excretion of conjugated waste products 
into maternal circulation.  
1.3.5.   MRP4 
 
Marcel Kool et al. first reported the distribution of MRP4 in human tissues and 
identified its localization to chromosome 13 in 1997 (Kool et al., 1997). One year 
later (1998), Kun Lee et al. successfully isolated the 5.9 kb MRP4 cDNA, which 
contains an open reading frame of 1,325 amino acids. This protein was originally 
designated as MOAT-B. This group also identified the location of MRP4 gene on 
13q32 and showed that MRP4 is expressed widely in human tissues, including 
prostate, lung, muscle, pancreas, testis, ovary, bladder, and gallbladder. Using 
immunostaining on prostate tissue, MRP4 was shown to localize in basolateral 
membranes as well as the basolateral cytoplasm region of basal cell (Lee et al., 1998, 
2000). 
 
In contrast with MRP1-related proteins, both MRP4 and MRP5 lack the third amino 
terminal membrane-spanning domain (MSD1). These two MRP transporters have 
their own distinctive drug resistance profiles, substrate selectivity and potential 
physiological functions. These two pumps do not confer resistance against natural 
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product anti-cancer agents, such as anthracyclines, vinca alkaloids or 
epipodophyllotoxins.  However, MRP4- and MRP5-mediated resistance against 
purines analogues and other nucleoside-based antiviral drugs have been reported.  
MRP4 gene was found to be amplified and overexpressed in a cell line resistant to 
anti-AIDS nucleotide analogues, such as 9-(2-phosphonylmethylethyl)adenine 
(PMEA), 9-(2-phosphonylmethoxyethyl)adenine (PMEG), azidothymidine (AZT) and 
2’,3’-dideoxy-3’-thiacytidine (3-TC) (Schuetz et al., 1999). A recent study showed 
that cells overexpressing MRP4 had a markedly increased resistance to the 
cytotoxicity of antiviral agent ganciclovir (GCV) (Adachi et al., 2002). Besides 
antiretroviral and antiviral agents, thiopurine anticancer drugs, 6-mercaptopurine (6-
MP) and 6-thioguanine (6-TG), are part of the MRP4 as well as MRP5 drug resistance 
profile (Schuetz et al., 1999; Lai et al., 2002). And a recent study showed that all 
major thiopurine monophosphates important in the efficacy of mercaptopurine 
treatment are transported by MRP4 and MRP5, although the substrate specificity of 
the two transporters differs (Wielinga et al., 2002). Interestingly, MRP4, similar with 
MRP1-3, and in contrast with MRP5, has been shown to confer resistance to a widely 
used anitmetabolite methotrexate (MTX) (Lee et al., 2000; Chen et al., 2002).  
 
By in vitro methods, it has been shown that this protein is also an organic anion 
transporter. Cells expressing MRP4 and MRP5 can enhance the excretion of GSH 
(Jedlitschky et al., 2000; Lai et al., 2002). Moreover, MRP4 can transport glucuronide 
conjugate, estradiol 17-β-D-glucuronide (E217βG) (Chen et al., 2001, 2002) and this 
transport has been shown to be inhibited competitively by estradiol 3,17-disulphate 
and taurolithocholate 3-sulphate (Zelcer et al., 2003). The transport of 
dehydroepiandrosterone 3-sulphate by MRP4 was also recently demonstrated (Zelcer 
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et al., 2003). In addition, MRP4 and MRP5 have the facility for the MgATP-
energized transport of cAMP and cGMP, a feature that suggests that their 
involvement in the regulation of intracellular cyclic nucleotide levels. However, 
affinity for cAMP of MRP4 is 9-fold higher than that of MRP5. By contrast, its 
affinity for cGMP is 5-fold lower than that of MRP5. These features of MRP4 suggest 
that it may play a more prominent role in modulating cAMP signal transduction 
pathway than does MRP5 (Jedlitschky et al., 2000; Chen et al., 2001; van Aubel et 
al., 2002; Lai et al., 2002). 
1.3.6.   MRP5 
 
MRP5 was cloned with the aid of EST database (Athkmets, et al., 1996). It is 
expressed ubiquitously, with the highest level in skeletal muscle, and localized in the 
basolateral membrane as MRP4 is (McAleer, et al., 1999). MRP5 gene is notable for 
its four transcripts with different size of 10 kb, 6.0 kb, 5.5 kb, and 1.6 kb (Suzuki et 
al., 1997, 2000).  
 
Unlike the other MRP proteins, MRP5 shares the same structure (Belinsky et al., 
1998, Figure 1.2) and the functionally similarity with MRP4. It has almost the same 
drug resistance profile and confers resistance to antiviral and anticancer nucleotide 
analogues: PMEA, 6-TG and 6-MP (Wijnholds et al., 2000). In addition, MRP5 has 
been shown to function as an ATP-dependent export pump for cyclic nucleotides 
cAMP and cGMP (Jedlitschky et al., 2000). 
 
Assays of the transport of anionic fluorochromes indicated that the substrate 
selectivity of MRP5 is not limited to phosphorylated compounds. MRP5 is also an 
organic transporter of GSH as well as DNP-GS conjugates and can be inhibited by 
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typical organic anion transport inhibitors, such as sulfinpyrazone and benzbromarone. 
However, in contrast to MRP4, MRP5-mediated transport of glucuronides, such as 
E217βG, has not been observed (Jedlitschky et al., 2000; McAleer et al., 1999; 
Wijnholds et al., 2000). 
1.3.7.   MRP6 
 
MRP6 was first amplified from a human kidney cDNA library and was assigned to 
MRP family on the basis of amino acids alignment (Belinsky et al., 1999). It is highly 
expressed in liver as well as kidney but to a low extent in a few other tissues (Kool et 
al., 1999b). Mutations in human MRP6 gene are the genetic basis of pseudoxanthoma 
elasticum, a disease that affects elastin fibers in the skin, retina, and blood vessels 
(Bergen et al., 2000). 
 
With regards to the functional characteristics, MRP6 was recently demonstrated an 
ATP binding as well as ATP-dependent active transporter for organic anions. It has 
been shown that the expression of MRP6 is specifically associated with the Mg ATP-
dependent transport. The substrates include glutathione S-conjugates (LC4 and DNP-
GS), cyclopentapeptide BQ123, an endothelin receptor antagonist, but not glucuronate 
conjugates (E217βG). Moreover, investigations of in vitro transport properties and 
drug resistance activity of MRP6 showed that MRP6 can mediate low-level resistance 
to several natural product agents. These compounds include etoposide, teniposide, 
doxorubicin, and daunorubicin. These results indicate that MRP6 is a glutathione 
conjugate pump and may confer low-level resistance to certain anticancer agents 
(Belinsky et al., 2002; Ilias et al., 2002). 
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1.3.8.   MRP7 
 
The MRP7 cDNA sequence encodes a 1,492 amino acids ABC transporter. The 
structural architecture of this protein resembles that of MRP1-related proteins in that 
its transmembrane helices are arranged in three transmembrane domains. However, a 
conserved N-linked glycosylation site is not found at the N-terminus of MRP7. MRP7 
transcript was detected in a variety of tissues at low levels (Hopper et al., 2001). For 
the physiologic function, it has been demonstrated that MRP7 can catalyze the 
MgATP-energized transport of the glucuronide E217βG. However the transport of 
glutathione LTC4 is modest and that of other established substrates of MRPs can not 
be detected (Chen et al., 2003). This finding indicates that MRP7 is a lipophilic anion 
pump and a component of the ATP-dependent efflux system involved in the cellular 
extrusion of lipophilic compounds.  
1.3.9.   MRP8 and MRP9 
 
Two new human ABC transporters, MRP8 and MRP9, were cloned from a cDNA 
library of human adult liver. Phylogenetic analysis determined that MRP8 and MRP9 
genes are derived by duplication, and the predicted amino acid sequences of both gene 
products showed a high similarity with MRP5. The transcripts of MRP8 and MRP9 
genes were detected by PCR in various adult human tissues, including liver, lung, and 
kidney, as well as in several fetal tissues. 
 
With regards to clinical characteristics, MRP8 and MRP9 are mapped to a region 
harboring gene(s) for paroxysmal kinesigenic choreoathetosis (PKS). PKS is a 
disorder characterized by recurrent, frequent attacks of involuntary movements and 
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postures. Therefore the two genes represent positional candidates for this disorder 
(Tammur et al., 2001; Yabuuchi et al., 2001). 
 
1.4.  Identification of domains and amino acid residues for 
determining substrate specificity of MRP transporter 
1.4.1.   Localization of substrate specificity domain 
 
Most of the multidrug resistance proteins of clinical importance are ATP-binding 
cassette transporter that confers resistance to a brand spectrum of drugs in tumor cells 
while functioning as primary active transporters of organic anions in normal cells. 
However, what determines the ability of MRPs to transport structurally unrelated 
cytotoxic drugs and conjugated organic anions remains largely unknown. Recently, 
structure/function studies have begun to identify domains and individual amino acid 
residues that are believed to be involved in determining substrate recognition and 
transport specificity in MRP1-related proteins. 
 
MRP1-3 consists of 17 transmembrane segments or helices (TMs) organized in three 
membrane-spanning domain regions [MSD1 (TM1-5), MSD2 (TM6-11), and MSD3 
(TM12-17)] (Deeley and Cole, 1997). Using a series of 5’-truncated MRP1 molecules 
expressed in insect cells, the linker region between MSD1 and MSD2 was found to be 
necessary for transporting LTC4 (Bakos et al., 1998; Gao et al., 1998). Moreover, it 
has been reported that monoclonal antibodies which can recognize the conformation-
dependent epitopes around amino proximal or carboxyl proximal nucleotide-binding 
domain (NBD) of MRP1, inhibited the ATP-dependent transport of LTC4 without 
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affecting the photolabeling of MRP with 8-azido-[α-32P] ATP (Hipfner et al., 1999). 
In addition, photoaffinity labeling studies have shown the presence of LTC4 labels 
sites in both the amino and carboxyl proximal halves of MRP1 and that labeling of the 
carboxyl proximal half of the protein is confined to a region encompassing TM14 to 
TM17 of MSD3 (Qian et al., 2001). Using photoreactive drug analogs, N- 
(hydrocinchonidin-8’-yl)-4-azido-2-hydroxybenzamide (IACI) and [125I]-iodoaryl 
azidorhodamine 123 (IAARh123), Daoud et al. have mapped major photoaffinity-
labeled sites to MRP1 sequences encoding TM10 and TM11 of MSD2 and TM16 and 
TM17 of MSD3 (Daoud et al., 2001). In contrast, 125I-labeled 11-azidophenyl 
agosterol A, a derivative of the polyhydroxylated sterol acetate, photolabeled only one 
site in the carboxyl proximal region of MRP1 (amino acids 932-1531), and it does so 
in a GSH-dependent manner (Qian et al., 2001). 
1.4.2.   Identification of key amino acids 
 
The importance of the amino acid residues located in the membrane-spanning 
domains was firstly demonstrated for MDR1 and CFTR in the ABC family. It was 
found that alterations in amino acid residues in TM6 and TM12 of MDR1 affect the 
function of this protein (Loo and Clarke, 1999), and the cationic charged amino acid 
(Arg352), a residue flanking the predicted cytoplasmic end of the TM6 segment, is a 
determinant for ion selectivity in CFTR (Sheppard and Welsh, 1999; Guinamard and 
Akabas, 1999). Recently, the specific amino acid residues involved in the recognition, 
binding, and transport of MRPs substrates are being identified. Using the hybrid 
mouse MRP1 and human MRP1 protein, Strde et al. have localized regions that are 
important for both anthracycline resistance and efficient transport of E217βG to the 
carboxyl terminal third of MRP1 (Stride et al., 1999). More detailed analyses of 
individual nonconserved amino acids within these regions subsequently revealed that 
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Glu1089 in the predicted TM14 is critical for the ability of MRP1 protein to confer 
anthracycline resistance (Zhang et al., 2001a). The same group has also shown that 
mutations of a nonconserved hydrophilic residue, Thr1242, within the putative TM17 
of MRP1 dramatically decreases the ability of the protein to confer drug resistance 
and to transport E217βG without significant effect on LTC4 transport (Zhang et al., 
2001b).  
1.4.2.1.  Aromatic amino acid Trp 
 
Another critical amino acid discovered by Cole’s group for the binding and transport 
of some MRP1 substrates and inhibitors is tryptophan (Trp), an aromatic polar 
residue. The important one is a highly conserved Trp residue at position 1246 at or 
near the predicted membrane-cytoplasmic interface of the most carboxyl proximal 
segment of the protein, TM17. Both conserved and non-conserved substitutions of the 
amino acid eliminated the ability of MRP1 to transport E217βG and to confer drug 
resistance but have only a relatively minor effect on LTC4 transport (Ito et al., 2001a). 
Substitutions of the analogous Trp residues in TM17 of MRP2 and MRP3 (Trp1254 
and Trp1242, respectively) have been subsequently shown to selectively affect the 
substrate specificity of these transporters but in a manner that is distinct for each 
protein (Ito et al., 2001b; Oleschuk et al., 2003). Furthermore, the 11 remaining Trp 
residues in predicted TM segments of MRP1 were mutated. Five of them Trp361 
(TM7), Trp445 (TM8), Trp459 (TM9), Trp553 (TM10) and Trp1198 (TM16) are also 
major determinants of MRP1 transport function (Koike et al., 2002). These findings 
suggest that the bulky polar aromatic indole side chain of these Trp residues 
contributes significantly to the transport activity and substrate specificity of MRP 
protein. 
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1.4.2.2.  Charged amino acids 
 
Beside the aromatic amino acid Trp, charged amino acid residues, particularly 
cationic amino acids, in the membrane-spanning domain are believed to play an 
important role in the recognition and transport of organic anions. Since many of 
relatively large hydrophobic domain as well as a hydrophilic domain have at least one 
anionic or cationic charge at physiological pH, it seems reasonable to suggest that 
charged amino acids in the TM segments of this protein might well play a role in 
determining its substrate specificity and transport activity (Zhang et al., 2001a; Ito et 
al., 2001a; Ryu et al., 2000).  
 
It has previously been noted that MRP1 contains a significantly greater number of 
potentially charged amino acids in its predicted TM α-helices than P-glycoprotein 
(Seelig et al., 2000). Hydropathy analyses predict that the first TM helix of MSD2, 
TM6, spans amino acids 320-340 and contains three potentially charged amino acids. 
Cole’s group has mutated Lys332, His335, and Asp336 in TM6, which are predicted to 
cluster in the exoplasmic leaflet of the membrane, and showed that individual 
substitution of these residues with a neutral of oppositely charged amino acid 
markedly affects the transport activity of MRP1 (Haimeur et al., 2002). Importantly, 
they showed that substitutions of Lys332 and to a lesser extent His335 selectively 
decrease the binding and transport of LTC4 and GSH while leaving the transport of 
other organic anions unchanged. In contrast, substitution of Asp336 showed no such 
selectivity, since mutation of this amino acid markedly reduces or eliminates transport 
of all MRP1 substrates and thus appears critical for the overall activity of the protein.  
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Similar site-directed mutagenesis was performed in rat MRP2 to identify the role of 
charged amino acids in determination of the substrate specificity of this transporter 
(Ito et al., 2001c). It was shown that the replacing of charged amino acid Lys325 
(TM6) and Arg586 (TM11) with non-charged residues results in a marked reduction of 
transport of DNP-SG and LTC4 while the affinity for E217βG increases several folds. 
This finding suggests that these two amino acid residues play an important role in 
distinguishing between glutathione and glucuronide conjugates.  
 
Amino acid residues in MRP4 involved in the recognition and transport of its 
substrates remain largely unidentified. To gain insight into the key amino acids that 
determine the substrate specificity, we aligned the sequence of MRP family (MRP1-8) 
and focused on the aromatic amino acid Trp995 and charged amino acid residues 
Glu103 and Arg362 (Figure 1.4). In the present study, we mutated the above analogous 
residues in MRP4 with both conserved and non-conserved amino acids and examined 












Figure 1.4  Alignment of predicted TM segments in MRP4 and the corresponding 
TM segments in other members of human MRP family. The relative conservations of 
(A) Glu103 (TM1), (B) Arg362 (TM6) and (C) Trp995 (TM12) in MRP super family are 
shown. The arrows to the amino acids in the sequences are identical to those in 










































































2. Aims and overview of study 
 
Multidrug resistance proteins (MRPs) are ATP-dependent export pumps that mediate 
the export of organic anions. A key feature of MRP (ABCC) proteins is the ability to 
transport anionic conjugates including glutathione-S-conjugates. MRP1, MRP2 and 
MRP3 are all able to facilitate the efflux of glutathione-S-conjugates. However, the 
ability of MRP4 to perform this transport has not been extensively investigated. This 
project was thus carried out to gain insight into this aspect. In addition, the role of 
highly conserved amino acids in determination of MRP4 substrate specificity was also 
examined. 
 
Figure 3.1 shows a flow chart of our approach. Human Hep G2 cells stably 
overexpressing MRP4 were used to perform cytotoxic assay as well as transport 
study. Inhibition study of transport activity by other MRP4 substrates and known 
MRP inhibitors were also carried out. Furthermore, using site-directed mutagenesis, 
we replaced three highly conserved amino acids among the MRPs predicted to be in 
the TM helices with conserved or non-conserved residues.  All mutants were 
expressed in transfected human Hep G2 cells at levels comparable with wild-type 
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3.  Materials and Methods 
3.1.  Mammalian cell culture 
3.1.1. Material 
Dulbecco’s Modified Eagle Medium (DMEM) was purchased from National 
University Medical Institute (NUMI). Other cell culture reagents were purchased 
from Life Technologies, USA, with the exception of glutamine and 
penicillin/streptomycin which were obtained from Sigma Chemical Co, USA. 
Blasticidin were purchased from Invitrogen, USA. 
3.1.2. Cell line and cell culture 
HepG2 cell and MDCK II cell stably expressing human MRP4 protein have been 
previously described (Lai and Tan, 2002). The blasticidine clones, v/Hep G2 and 
v/MDCK II were transfected with pcDNA6 vector and were included as controls. 
Cells were routinely grown in complete medium consisting of Dulbecco’s Modified 
Eagle Medium (DMEM), 1 mM sodium pyruvate, 2 mM glutamine, 0.1 mM non-
essential amino acids, 100 units/ml penicillin, 100 µg/ml streptomycin, 10% fetal 
bovine serum and 0.25 µg/ml blasticidin. The cells were grown at 37oC  
3.1.3. Initiating a new flask 
1ml frozen cells taken out from liquid nitrogen tank was thawed at 37°C and then 
diluted with 10 ml medium and centrifuged at 1000 x g for 5 min to remove the 
DMSO (dimethyl sulfoxide). After the supernatant was discarded, the pellet was 
resuspended in 7ml medium in a 25cm2 flask and kept growing in a humidified 
atmosphere of 95% air and 5% CO2.    
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3.1.4. Passaging cells 
Cells were passaged when the flask was 95% confluent. The cells were washed with 
1x PBS (phosphate-buffered saline, 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1,47mM KH2PO4, pH 7.4) twice after the old medium was removed. 2ml of 1x trypsin 
was added and spread over the 75cm2 flask. After 5 minutes incubation at room 
temperature for HepG2 cells and 20 minutes for MDCK cells, the cells were detached. 
The appropriate volume of cell suspension was then transferred to a new 75cm2 flask 
with 15 ml fresh medium. 
3.1.5. Harvesting cells 
After the spent medium was removed, the cells were washed twice with 1x PBS and 
trypsinised. The detached cells were resuspended in 10 ml DMEM and centrifuged at 
1000 x g for 5 min. The pellet was then resuspended in 1 ml PBS and centrifuged as 
above. The pellet was kept at -80°C.  
3.1.6. Freezing cells 
After the spent medium was removed, the cells were washed twice with 1x PBS and 
trypsinised. The detached cells were resuspended in 10ml medium and centrifuged at 
1000 x g for 5 min. The pellet from one 75cm2 flask was resuspended in 3ml fetal 
bovine serum containing 10%DMSO and then transferred to nunc cryotubes, which 
were firstly kept at -80°C for one week and then transferred to the liquid nitrogen tank 
for long-term storage. 
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3.2.  Functional study of MRP4 Protein 
3.2.1. Material 
6-thioguanine (6-TG), 6-mercaptopurine (6-MP), DL-buthionine (S,R) sulfoximine 
(BSO), carbonylcyanide m-chlorophenylhydrasone (CCCP), 1-chloro-2, 4-
dinitrobenzene (CDNB), methotrexate, benzbromarone, indomethacin, (±)-verapamil 
hydrochloride, cyclosporin A and equine liver glutathione-S-transferase (GST) were 
purchased from Sigma Chemical Co, USA. Glutathione (GSH) was obtained from 
ICN Biomedicals Inc, while monochlorobimane (MCB) was from Molecular Probes 
Inc, USA. 2’,2’-difluorodeoxycytidine (dFdC) was from Eli Lilly Company,  
Indianapolis. [3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium] / phenazine ethosulfate  (MTS/PES) reagent was 
supplied as the CellTiter 96 Aqueous One Solution Cell Proliferation Assay by 
Promega, USA. 
3.2.2. Cytotoxicity assay 
Cells were plated in triplicate at the plating density of 2.5 x 103 per well in 96-well 
tissue culture plate in a volume of 200µl of complete medium. After 24 hours 
incubation at 37oC, the medium was changed and drugs at various concentrations 
were added. 48 to 72 hours later, 20 µl of MTS/PES was introduced to each well. 
After incubation at 37oC for 30 min, absorbance was measured at the wavelength of 
490 nm. The data obtained were used to calculate the 50% growth inhibitory 
concentration (IC50) of the various compounds tested. At least five drug 
concentrations were used to determine the IC50 values. 
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3.2.3. Export assay with MCB 
3.2.3.1. Detection and measurement of transport activity  
Measurement of the formation and efflux of bimane-glutathione (bimane-GS) was 
carried out as the following. Cells were plated in triplicate at a plating density of 6 x 
105 cells per well into six-well plates, and incubated for 24 h at 37°C in a humidified 
atmosphere of 95% air and 5% CO2. The cells were then incubated with 1 ml DMEM 
containing 100 µM MCB at 10°C for 60 min. The plate was placed on ice and the 
cells were washed twice with cold Hanks balanced salt solution (HBSS, containing 
5.8 mM K+, 143 mM Na+, 1.3 mM Ca++, 0.8 mM Mg++, 146 mM Cl-, 0.8 mM 
phosphate, 4.2 mM HCO3-, and 10 mM Hepes, pH7.4). The cells were then incubated 
at 37oC in HBSS containing 5.6mM glucose. At the end of the experiment, the 
incubation buffer was removed. The cells were lysed in 0.2% sodium dodecyl sulfate 
(SDS) and protein determination was carried out using Bio-Rad Protein Dye with 
bovine serum album dissolved in 0.2% SDS as the standard. 
 
0.2 ml aliquots of incubation buffer as well as 0.2 ml aliquots of cell lysate were 
collected. The fluorescence of all collected samples were read using an excitation 
wavelength of 385 nm and an emission wavelength of 478 nm in a Gemini XS 
microplate spectrofluorometer from Molecular Devices Corp., USA. 
 
To quantify the amount of bimane-GS, a series of bimane-GS standards were 
generated. 0-48 µM of GSH, 100 µM of MCB, 1U/ml equine liver GST in HBSS 
buffer (or in HBSS buffer containing 0.2% SDS for cell lysate) were mixed and 
incubated until no increase in fluorescence was observed. This takes 30 mins of 
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incubation at 37oC. Following this, a calibration curve was obtained and the 
fluorescence of the samples was then correlated with the curve. 
 
Cell viability was determined by trypan blue staining at the end of the incubation 
period for efflux. 
3.2.3.2. Effects of CCCP, CDNB and inhibitors  
To determine the effect of CCCP on transport of bimane-GS, efflux was carried out as 
described above in HBSS/glucose containing 2.5 µM CCCP. 
 
For assays to examine the effects of CDNB on bimane-GS efflux, the cells were 
incubated in 1 ml DMEM containing 100 µM MCB at 10°C for 60 min together with 
CDNB at different concentration. The efflux was carried out as described above in 
HBSS/glucose buffer. 
 
For assays to examine the effects of 6-TG, methotrexate, benzbromarone, 
indomethacin or verapamil, the cells were incubated in 1 ml DMEM containing 100 
µM MCB at 10°C for 60 mins together with the inhibitor. Controls consist of cells 
incubated with the respective solvents for each of the compounds used. The efflux 








3.3.  Cloning site-directed mutated MRP4 cDNA 
3.3.1.  Materials 
Primers for PCR were synthesized at the Operon Technologies. INC or GENSET 
Singapore Biotech. Pte Ltd. Luria Broth (LB) medium and 10x TAE buffer were 
purchased from National University Medical Institute (NUMI). Ampicillin was 
obtained from Sigma. All molecular biology reagents were obtained from New 
England Biolabs, USA. The pBluescript vector was from Strategene, USA while 
pcDNA6 vector and blasticidin selection marker were purchased from Invitrogen, 
USA.  
3.3.2.  Site-directed mutagenesis 
3.3.2.1. Primer design 
PCR-based overlap extension method was used to generate site-directed mutagenesis 
of the MRP4 open reading frame (ORF).  Four primers are designed as follows. One 
pair of primers is used to amplify the DNA that contains the mutation site together 
with downstream sequence. The reverse primer (RM) contains the mutation to be 
introduced into the template DNA, whereas the forward primer (F) complements 
completely to the template with a restriction site in the 5’ region to facilitate 
subcloning of the mutated segment of DNA. The second pair of primers is used to 
amplify the DNA that contains the mutation site together with upstream sequence. 
The forward primer (FM) contains the mutation whereas the reverse one (R) 
complements the template with another restriction site in the 3’ region. Primers used 




The first round PCR contained two separate reactions using two sets of primers and 
was used to amplify overlapping fragments. The mutation site is located in the overlap 
region and is therefore present in both sets of amplified fragments. Using the two 
both-end primers without mutations (F and R), the second round PCR was preceded 
using a mixture of the first round PCR products as template to generate a full-length 
mutant fragment (Figure 3.1). 
 
PCR (polymerase chain reaction) was performed using the QIAGEN PCR system. 
50µl reaction was prepared in a 200µl PCR tube as follows: 5µl 10x PCR buffer, 1µl 
10mM dNTPs mixture, 4µl MgSO4 (25mM), 1µl template DNA (1µg), 1µl of both 
primers (0.2µg/ml) and 0.5µl Taq polymerase (5 units) were mixed together and 
36.5µl ddH2O was added to top up the volume to 50µl. The reaction was allowed to 













Initial denaturation         94°C             3 min 
 
Denaturation                  94°C              1 min                               
Annealing                      55°C              1 min                           30 cycles 
Extension                       72°C              1 min/kb DNA 
 
Final extension               72°C             10 min 
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TABLE 3.1 Primers for mutagenesis. Substituted nucleotide are underlined; small 
letters indicate restriction enzyme recognition sequence. 
 
 
Name of mutant Primers 
E103N     
(original amino acid E 
was mutated to 
nonconserved amino 
acid N) 
F:  5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’ 
RM: 5' GGC ACT GTT CTC AAT TAA 3' 
FM: 5' GAG AAC AGT GCC AAA GTA 3' 
R: 5’ TGC GAA TTC ATG CTG CCC GTG TAC CA 3’ 
E103D    
(original amino acid E was 
mutated to conserved amino 
acid D) 
F: 5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’ 
RM: 5' T GGC ACT GTC CTC AAT TAA 3’ 
FM: 5' TTA ATT GAG GAC AGT GCC A 3' 
R: 5’ TGC GAA TTC ATG CTG CCC GTG TAC CA 3’ 
R362L 
(original amino acid R was 
mutated to nonconserved 
amino acid L) 
F: 5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’  
RM: 5' AACCGTCAGCAGCACAGCCCCA 3' 
FM: 5' GGGGCTGTGCTGACGGTTA 3' 
R: 5’ AGA GTT AAC AAG GAC GTA GA 3’ 
W995C 
(original amino acid W was 
mutated to nonconserved 
amino acid C) 
F: 5’ CTT gtt aac TCT TCA CAA 3’ 
RM: 5’GTCGAACACAACACTGAAACATC 3’ 
FM: 5’GATGTTTCAGTGTTGTGTTCGAC 3’ 
R: 5’TGT ctc gag GAT TCC CAG TGC TGT CTC3’ 
W995F 
(original amino acid W was 
mutated to conserved amino 
acid F) 
F: 5’ CTT gtt aac TCT TCA CAA 3’ 
RM: 5’GTCGAACACAGAACTGAAACATC 3’ 
FM: 5’GATGTTTCAGTTCTGTGTTCGAC 3’ 













3.3.2.3.  Gel extraction and purification of DNA 
The PCR products were subject to gel electrophoresis to ensure that the products were 
of the correct size. To prepare the gel, agarose (BioRad) was dissolved in 1x TAE 
buffer (Tris-Acetate-EDTA: 4mM Tris, 0.2mM EDTA and 1.14‰ glacial acetic acid 
with pH at 7.8) with 500µg/L ethidium bromide (BioRad) for staining. 
Electrophoresis was performed at 80-100 volts for 30-45 minutes and a photograph 
was taken with the gel on the UV transilluminator.  
 
QIAquick Gel Extraction Kit (QIAGEN) was used to perform DNA gel extraction and 
purification. After agarose gel electrophoresis, the DNA fragment of interest was 
excised and then weighed. 3 volumes of buffer QG to 1 volume of gel slice were 
applied to dissolve gel slice. The completely dissolved sample was then load on to a 
QIAquick column sitting in a 2-ml collection tube to bind the DNA. The tube was 
centrifuged at 12,000 x g for 1 minute and the flow-through was discarded. 0.75ml of 
buffer PE was then added to the column and the tube was centrifuged at 12,000 x g 
for 1 minute twice to allow the buffer PE to flow through completely. The column 
was then placed in a clean 1.5ml tube. 30µl of Buffer EB was added directly onto the 
column to elute the DNA. After standing for several minutes at room temperature, the 





3.3.3.  TA sub-cloning 
3.3.3.1. Ligation of PCR products to a TA cloning vector 
The pGEM-T vector system (Promega) was used for TA cloning (Figure 3.2). The T 
vector with unpaired 3’ thymidyl residue can be readily ligated with the PCR products 
containing the additional single adenine generated by Taq polymerase at the 5’ ends. 
The vector contains an ampicillin resistance gene and a β-galactosidase gene for 
ampicillin and blue/white selection. 
 
 
Figure 3.2 pGEM-T vector from Promega. The pGEM®-T Vector is prepared by 
cutting Promega's pGEM®-5Zf(+) Vector with EcoR V and adding 3´ terminal 
thymidine to both ends. 
 
 
A 10µl ligation reaction system consisted of 1µl pGEM-T vector (60 ng), 1µl T4 DNA 
ligase (5 units), 5µl 2x rapid ligase buffer (all from the pGEM-T vector system kit) 
and 3µl PCR product purified by gel extraction and was incubated for at least 2 hours 
at room temperature. 
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3.3.3.2. Culture and storage of bacteria cells 
Luria Broth (LB) containing 10g of tryptone, 5g of NaCl, and 5g of yeast extract in 1 
L sterile water with pH at 7.4 was used for bacteria culture. LBA (LB with 
Ampicillin) medium and LBA-agar plate containing 100µg/ml Ampicillin were used 
for selection of cells carrying the vector. All preparations were kept at 4°C till 
required. 
 
The bacteria used for transformation is E. coli and the strain is DH5α. The bacteria 
was incubated in LB/LBA broth, or streaked on LB/LBA plates. Frozen stocks in 
LB/LBA medium containing 10% sterile glycerol were kept at -20°C for long term 
storage. 
3.3.3.3. Preparation of competent E. coli cells 
CaCl2 was used to treat the bacteria cells. A single colony from a freshly streaked 
plate was picked up and inoculated in 3ml of LB medium. The culture was incubated 
overnight at 37°C with vigorous shaking at 200 x g. 1ml of the bacteria culture was 
transferred into another 20ml of LB the next day and incubated at 37°C with vigorous 
shaking for 40 minutes or until the absorbance value of the culture reached 0.3 – 0.4 
at 600nm.  The cells were harvested by centrifugation at 3,000 x g for 5 minutes at 
4°C and the bacteria pellet was resuspended in 5ml ice-cold 0.1M CaCl2. After 15 
minutes incubation on ice, the cells were spun again and the pellet was resuspended in 
1ml of cold 0.1M CaCl2. After another 15 minutes incubation on ice, the competent 
cells were ready for transformation. 
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3.3.3.4. Transformation 
5µl of the ligation product was diluted with 25µl sterile TE buffer to decrease the 
concentration of glycerol in the ligase buffer. 200µl of competent cells was added to 
30µl of the diluted sample and then allowed to stand on ice for 30 minutes.  The 
sample was incubated in the 37°C water bath without shaking for 2 minutes and 
promptly transferred back on ice. After 5 minutes, 500µl of LB was added and the 
sample was incubated at 37°C with vigorous shaking for 1 hour. 1.25mg X-gal 
(Biorad) and 5nmol IPTG (Sigma) were then spread onto a LBA plate. 300µl of 
transformed cells was spread on each plate and the plates were then incubated 
overnight at 37°C. 
3.3.3.5. Selection and screening 
Single white colonies were picked up and inoculated in 3 ml LBA medium in loosely 
capped 15ml tubes the next day. The cultures were incubated overnight at 37°C with 
vigorous shaking and used for further analysis. 
3.3.3.6. DNA extraction: mini prep 
Solutions used for mini preparation of plasmid DNA were prepared in advance. 
Solution I consists of 25mM Tris (pH 8.0), 10mM EDTA (pH 8.0) and 50mM glucose 
while solution II consists of 0.2M NaOH and 0.1% SDS. Freshly prepared solution III 
consists of 3.0 M potassium acetate and 0.5 M acetic acid, pH 4.8. 
  
1.5ml of overnight bacteria culture was centrifuged at 12,000 x g for 1 minute and the 
pellet was resuspended in 100µl of ice-cold solution I by vigorous vortex. 200µl of 
solution II was then added and the tube was immediately inverted 5 times to mix. 
Following 2 minutes of incubation on ice, 150µl of cold solution III was added and 
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the tube was then vortexed shortly to mix again. After 5 minutes incubation on ice, 
the tube was centrifuged at 14,000 x g for 5 min and the supernatant was transferred 
to a new tube. 0.9ml of 100% ethanol was then added to precipitate the DNA and the 
mixture was vortexed shortly. After 5 minutes incubation at room temperature, the 
tube was centrifuged for another 5 min and the pellet was rinsed with 1ml of 70% 
ethanol. The tube was then spun again. After carefully removing the supernatant, the 
pellet was dried in the speed-Vacuum machine for 10-15 min and then dissolved in 
25µl of TE buffer containing 20µg/ml RNase (Promega). The samples were stored at -
20°C and used for further analysis. 
3.3.3.7. Restriction enzyme digestion 
The appropriated restriction enzymes (NEB) were used to digest the plasmid. They 
were EcoR I and EcoR V for clone E103D, E103N and R362L and Hinc II and Xho I 
for clone W995C and W995F. The appropriate corresponding buffer was used for 
each digestion. 
 
A digestion reaction mixture consisted of 0.25µl (2-5 units) of each enzyme, 1µl of 
10x buffer, 4µl (1-2 g) of DNA template and 3.5µl of sterile water and was incubated 
at 37°C for 2-3 hours. Agarose gel electrophoresis was then carried out to analyze the 
digest. 
3.3.3.8. DNA extraction: midi-prep 
Qiagen midi plasmid preparation kit was used to perform a larger scale plasmid 
preparation and purification (midi-prep). 1ml bacteria culture carrying the correct 
plasmid was grown in 100ml of LBA medium at 37°C with vigorous shaking 
overnight. Bacteria cells were harvested by centrifugation at 5,000 x g for 15 min at 
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4°C the second day. Cell pellet was resuspended completely in 4ml of ice-cold Buffer 
P1 by vortex. 4ml of buffer P2 was added and the tube was then inverted several 
times to mix. After 5 minutes incubation at room temperature, 4ml of cold buffer P3 
was added and the tube was inverted several times again. Following 15 min 
incubation on ice, the tube was then centrifuged at 13,000 x g for 30 minutes at 4 °C. 
The supernatant was transferred to a QIAGEN-tip 100 column that had been 
equilibrated with 4ml of Buffer QBT in advance and was allowed to flow through the 
column by gravity. The column was then washed twice with 10ml buffer QC each 
time and the DNA was eluted with 5ml Buffer QF. The eluant was collected in a new 
tube and mixed with 3.5ml isopropanol (Sigma). After 15 minutes of incubation at 
room temperature, the tube was centrifuged again. The pellet was rinsed with 1.5ml 
70% ethanol and centrifuged again. The pellet was then dried in the speed-vacuum 
machine and dissolved in 100µl TE buffer. 
 
The concentration and the purity were determined by measuring absorbance at 260 
nm and 280 nm. The DNA was subjected to appropriate restriction enzyme digestion 
followed by agarose gel electrophoresis analysis and the identity was confirmed by 
DNA sequencing. The remainder DNA was stored at –20 °C. 
3.3.3.9. DNA sequencing 
BigDye TerminatorTM Cycle Sequencing Ready Reaction Kit obtained from ABI 
PRISM Corp was used for DNA sequencing. A typical 20µl of sequencing reaction 
mixture consisted of 8µl of Terminator Ready Reaction mix, 1µl of DNA template, 
1µl of 50µM appropriate primer (forward & reverse primer respectively) and 10µl of 
ddH2O. Thermal cycling was carried out according to the following program: 25 
cycles of denaturation at 96 °C for 30 sec, annealing at 50°C for 15 sec and extension 
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at 60°C for 4 min. 2µl of 3 M sodium acetate and 50µl of 95% ethanol were used to 
precipitate the extended DNA. After 15 minutes of incubation at room temperature, 
sample was centrifuged at 12,000 x g for 30 min. The supernatant was then carefully 
aspirated and the pellet rinsed with 250µl of 70% ethanol and centrifugation for 5 
min. The air-dried sample was sent to the NUMI sequencing lab for sequencing. The 
result was compared to the published MRP4 sequence (GenBank access number 
AF071202). 
3.3.4.  Plamid construction 
 
pBlueScript SK II (+) (pBS) is a cloning vector with the cloning sites of EcoR I, EcoR 
V, Hinc II and XhoI present sequentially that was used to subclone MRP4 whereas 
pcDNA6/V5-His (pcDNA6) is an eukaryotic expression vector with the V5 epitope 
and a polyhistidine sequence at the end of multiple cloning site that can be used to 



















Figure 3.3 Map of pcDNA6/V5-His vector (Invitrogen). The EcoR I and Xho I sites 
were used for cloning the MRP4 full-length gene. 
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Full- length MRP4 cDNA without the stop codon, but with EcoRI and XhoI 
restriction sites engineered at the 5’- and 3’- ends had been subcloned into pBS and 
pcDNA vector to generate MRP4-pBS and MRP4- pcDNA6 constructs. From the 
clones in pGEM-T vector, the mutated fragments with the restriction enzyme sites of 
EcoR I and EcoR V at each end were digested and inserted directly to MRP4-
pcDNA6. However, clones with the restriction enzyme sites of Hinc II and Xho I at 
each end had to be transferred to MRP4-pBS construct first before being ligated into 
the expression vector since the Hinc II restriction enzyme site is an unique site in pBS 





Figure 3.4. Schematic diagram of full-length MRP4. MRP4 DNA was cloned into 
pBS and pcNDA6 vector by adding EcoRI restriction enzyme sequence just before the 
start codon ATG and XhoI restriction enzyme sequence after the last codon coding of 
MRP4 cDNA. EcoRV and HincII are the unique restriction digestion sites within the 
MRP4 cDNA. 
 
         Indicates the amino acid site where site-directed mutagenesis was performed. 
 
The MRP4- pBS construct containing the mutant was then digested by EcoR V and 
Xho I and the digested fragment was then inserted into the same enzyme-digested 
pcDNA6. The full-length MRP4-pcDNA6 constructs with the specific site mutations 




(EcoRI)ATG           EcoRV                                   HincII                                       XhoI 
 
 
               E103    R362                                                           W995 
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3.4. Transfection and expression of mutated MRP4 
3.4.1. Material 
OPTI-MEM®I Reduced Serum Medium, Lipofectamine reagent and anti-V5 
monoclonal antibody were purchased from Invitrogen, USA. Anti- MRP4 antibody 
was kindly provided by Dr. Gary Kruh’s lab. 
3.4.2. Transfection and selection 
Mutant MRP4 in pcDNA6 vector was transfected into Hep G2 cells. Wild-type MRP4 
as well as empty pcDNA6 vector were included as the controls. Briefly, one day 
before transfection, HepG2 cells were plated into six-well plates (35-mm) at the 
plating density of 3x105 cells per well. 4µg of DNA of each sample precipitated from 
midi plasmid preparation was dissolved in 100µl of OPTI-MEM®I Reduced Serum 
Medium while 6µl of Lipofectamine reagent was diluted with another 100µl of OPTI-
MEM medium for each transfection.  These two were then mixed gently and 
incubated at room temperature for 45 minutes to allow DNA-liposome complexes to 
form. During the incubation, the cells in the six-well plates were washed twice with 
the OPTI-MEM medium and incubated in 0.8ml of OPTI-MEM medium. 200µl of the 
mixture was then gently applied into each well. Following 5 hours incubation in a 
37°C humidified incubator, 2ml of complete DMEM medium was applied into each 
well and the cells were incubated overnight.  From the second day, complete DMEM 
medium with 1µg/ml blasticidin for selection was changed every 2 days for about 3 
weeks to remove the debris of the dead cells and to allow the colonies of resistant 
cells to grow. When single colonies were observed, they were transferred individually 
into a 96-well plate and allowed to expand until there were sufficient cells to grow in 
a 75cm2 flask. Localization and expression levels of MRP4 protein in the blasticidin-
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resistant cell population were then determined by immunostaining and western 
blotting analysis.  
3.4.3. Immunostaining 
Cells were grown on a glass cover slide until 70% confluence. Cells were first fixed 
with methanol for 20 minutes at –20°C. After washing for 4 times (5min for each 
washing), the cells were permeablized with 0.02% Triton X-100 (BioRad) in PBS 
buffer for 15 minutes. The cells were then stained with an anti-MRP4 antibody diluted 
in the ratio of 1:100 in PBS buffer containing 3% BSA for 1 hour.  After washing 4 
times, the cells were incubated with an anti-mouse secondary antibody conjugated to 
FICT diluted in the ratio of 1:40 in PBS buffer containing 3% BSA for 1 hour.  Cells 
were thoroughly washed 4 times. To counter stain the cell, cells were incubated in 
1µg/ml propidium iodide (Sigma) solution for 10 min and then washed twice. 
 
The cells were viewed with a fluorescent microscope. The FITC-conjugated 
secondary antibody has an excitation wavelength of 495 nm and an emission 
wavelength of 525 nm.  
3.4.4. SDS-PAGE gel electrophoresis 
3.4.4.1. Preparation of reagent and solution 
To prepare 4x buffer for separating gel (1.5M Tris-HCl), 18.17g Tris base and 4ml 
10% SDS were dissolved in 100ml H2O and HCl was used to adjust the pH to 8.8 
whereas 6.06g Tris base was used for stacking gel buffer (0.5M Tris-HCl), pH 6.8. To 
prepare 10x polyacrylamide running buffer, 30g Tris base, 144g lysine and 100ml 
10% SDS were dissolved in 1L H2O whereas 0.0185g bromophenol blue, 0.8g SDS, 
10ml 4x stacking buffer, and 8ml glycerol were mixed together and completely 
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dissolved to make up SDS 4x sample buffer. Acrylamide solution (30%) consists of 
30g acrylamide and 0.8g bisacrylamide in 100ml H2O. 10% AP (ammonium 
persulfate from Sigma) solution was prepared freshly just before use. 
3.4.4.2. Preparation of sample 
The cell pellet harvested from a 75cm2 flask was resuspended in 200µl PBS, and 
allowed to thaw and freeze three times to break the cells. To ensure the same amount 
of protein from different samples was applied, protein determination was carried out 
using the Bio-Rad Protein Dye with bovine serum album as the standard. About 30µl 
of suspension (corresponding to 0.5mg protein) was mixed with 10µl of SDS 4x 
sample buffer and 1.5µl β-mercaptoethanol, and the mixture boiled in water for 10 
min to completely denature the protein.  
3.4.4.3. Procedure 
The resolving gel solution was mixed and allowed to degas before AP and TEMED 
were added. The reagents were quickly mixed and poured into a mini-gel casting 
chamber. A depth of 2.5 cm from the top was left empty. Water was overlaid to cover 
the separating gel. When the separating gel had solidified, the water was removed; the 
stacking gel was prepared and poured on top of the separating gel. A comb was 
inserted into the stacking gel. The comb was removed after the stacking gel solidified. 
Gel formulation at different concentration was shown in Table 3.2. 
 
20 µl of sample or 10µl of prestain protein ladder (BioRad) was loaded into each well. 
The gel was then electrophoresised at 140 volt for 60 min or till the dye front ran near 
the bottom of the gel. 
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Table 3.2  Composition of SDS-PAGE gel.  
 
 Separating gel Stacking gel 
Gel percentage 7.5% 10% 12.5% 4% 
H2O 1.8 ml 1.5 ml 1.2 ml 1.6 ml 
Acrylamide solution 0.95 ml 1.25 ml 1.55 ml 0.25 ml 
Separation buffer 0.95 ml 0.95 ml 0.95 ml  
Stacking buffer    0.625 ml 
AP 56 µl 56 µl 56 µl 37.5 µl 
TEMED 2.5 µl 2.5 µl 2.5 µl 2.5 µl 
 
 
3.4.5. Western Blotting 
3.4.5.1. Preparation of solutions 
1x transfer buffer consisted of 25mM Tris, 0.2 M glycine, 0.05% SDS and 20% 
methanol with pH at 8.3 while 1x TBS-T buffer of 20mM Tris, 137mM NaCl and 
0.1% Tween-20 with pH at 7.4. Blocking buffer was 1x TBS-T buffer with 5% skim 
milk. Western blotting analysis (ECL) kit was abstained from Amersham.  
3.4.5.2. Procedure 
The separation gel was soaked in the transfer buffer together with the nitrocellulose 
membrane and filter paper of the same size as the gel. The gel sandwich was stacked 
in the order of filter paper, gel, membrane and filter paper. The proteins were transfer 
from gel onto nitrocellulose membrane at 200 mA for 60 min at 4°C. The membrane 
was then blocked overnight in blocking buffer. After washing with TBS-T buffer 
twice, the membrane was cut to two pieces to separate MRP4 protein and actin.  The 
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membrane was then incubated in 7 ml of blocking buffer containing 1:1000 diluted 
anti-V5 antibody (Invitrogen) or 1:100 diluted anti-actin antibody (Sigma, USA) for 2 
hours. The membrane was then washed with TBS-T buffer twice and then incubated 
in blocking buffer containing 1:1000 diluted anti-mouse antibody for MRP4 or 1:5000 
diluted anti-rabbit antibody for actin (ECL kit, Amersham) for 1 hour. The membrane 
was then thoroughly washed with TBS-T buffer to remove the excess secondary 
antibody. Finally the membrane was submerged in a mixture of equal volume of 
luminol solution and stable peroxide solution (ECL kit, Amersham), and incubated for 
5 min. The membrane was removed from the mixture and placed against the film 
(Pierce) in the cassette. The film was developed after sufficient exposure. 
  
3.4.6. Expression level quantitation 
Relatively levels of protein expression were estimated by densitometric analysis using 
the Analytical Imaging Station software (Imaging Research Inc, USA)  
 
3.5. Functional study of mutated MRP4 protein 
3.5.1. Cytotoxicity assay 
Measurement of cell growth inhibition was carried out as previously described in 
section 3.2.2.1. However, only two drugs: 6-TG and DFDC were used.  
 
 
3.5.2. Export assays with MCB 
 
Measurement of the formation and efflux of bimane-glutathione (bimane-GS) was 




4.1. Functional study of MRP4 protein 
4.1.1. Cytotoxic assay 
MRP4 has been shown to act as a plasma membrane drug efflux pump and can confer 
resistance to certain nucleoside analogs. In this study, MRP4 full-length cDNA was 
stably transfected into human liver HepG2 cells and dog kidney MDCKII cells. 
Empty pcDNA6 vector was carried out simultaneously as the control. In the initial 
experiment, 6-thioguanine (6-TG) was applied to both of the two cell lines to examine 
the drug resistance of MRP4 protein. Resistance was more obvious in the HepG2 cell 
line than in the MDCKII cell line. Thus HepG2 cells were used in all further 
experiments. Several other nucleoside compounds were then examined. Obvious 
resistance was observed in MRP4/HepG2 clone to two anti-cancer drugs: 6-
thioguanine (6-TG) and gemcitabine (dFdC) while there was little resistance to two 
other drugs: 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU). However, another 
therapeutic drug 5-fluoro-2'-deoxyuridine (5-FdU) was shown to have similar effects 
on MRP4-transfected and control cells while the drug cytosine β-D-arabino-
furanoside (CAF) did not show any effect on both the control and the MRP4 
transfected cells at concentration as high as 1mM.  
 






Table 4.1.  Resistance of MRP4/Hep G2 and MRP4/MDCK II cells to nucleoside  
                        drugs.  
 
The cells were exposed to dFdC for 72 hours while to the other compounds for 48 
hour. MTS reagent was then added and cells were incubated for 60 minutes. The 
absorbance at 490 nm was measure. IC50 is the concentration at which cell growth is 
inhibited by 50%. At least five drug concentrations were used to determine IC50 
values. Each concentration was carried out in triplicate. The fold resistance is the ratio 




IC50 (µM) Cell line 
6-TG dFdC 6-MP 5-FU 5-FdU 
MRP4/HepG2 
 29.5+5.0 83.9+16.6 82.1+18.9 481.6+65.1 45.8+11.3
V/HepG2 
(control) 8.1+0.9 21.7+1.1 47.8+6.9 269.6+13.5 39.0+3.7 
Fold resistance 
 3.65 4.33 1.72 1.79 1.17 
MRP4/MDCKII 
 78.1+5.0 --- --- --- --- 
V/MDCKII 
(control) 54.4+13.6 --- --- --- --- 
Fold resistance 














4.1.2.  Export of bimane-GS by MRP4/Hep G2 cells 
The bimanes are a family of heterocyclic compounds that form fluorescent adduct 
with thiols. Monochlorobimane (MCB) has been shown to form a fluorescent adduct 
with GSH specifically and preferentially over other thiols (Fernandez-Checa, et al., 
1990). MCB enters the cell through diffusion. Within the cell, MCB is conjugated 
with GSH by cellular glutathione-S-transfereases. The resulting hydrophilic bimane-
glutathione can only leave the cell via carrier-mediated transport (Zhang et al., 1996; 
Terlouw et al., 2001; Ishikawa et al., 1994). In this study, the formation and efflux of 
the fluorescent bimane-GS adduct was examined using MRP4 overexpressing cells. 
Cells were first loaded with 100 µM MCB. This was carried out at 10oC to ensure that 
little active efflux of the bimane-GS will take place. Upon warming to 37oC, cells 
preloaded with MCB showed a time dependent efflux of bimane-GS.  
 
Amount of bimane-GS present in the incubation buffer of MRP4/Hep G2 cells 
increased from 6.6 + 0.7 nmol/mg protein to 18.0 + 0.4 nmol/mg protein over a period 
of 15 mins (Figure 4.1.A). This is mirrored by a decrease in cellular bimane-GS levels 
(Figure 4.1.B). The efflux of bimane-GS from MRP4/Hep G2 cells is rapid and 
tapered off after 10 mins as intracellular bimane-GS levels decreases and becomes 
limiting. All subsequent export assays were thus carried out after 10 mins of 
incubation at 37oC. After 15mins, more than 85% of the conjugate has been 
transported out of the cell (Figure 4.1.C). In contrast, the efflux from v/Hep G2 
increased more gradually from 3.2 + 0.9 nmol/mg protein to 14.3 + 0.8nmol/mg 
protein over the same period (Figures 4.1.A and 4.1.C). Export of bimane-GS from 
v/Hep G2 cells is probably mediated by MRP proteins that are endogenously 
expressed in HepG2 cells (Lee et al., 2001; Roelofsen et al., 1997). At all time points 
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beyond 0 min, export of bimane-GS from MRP4/Hep G2 cells was significantly 
higher than that from v/Hep G2 cells. The higher efflux is not due to differences in 
conjugation capacity of the cells as the total synthesis of bimane-GS in MRP4/Hep 
G2 cells (20.5 + 0.5 nmol/mg protein/15 mins) and v/Hep G2 cells (22.9 + 0.8 
nmol/mg protein/15 mins) is comparable. 
 
Figure 4.1.  Efflux of bimane-glutathione from control and MRP4 overexpressing 
cells.  
Cells were preincubated at 10oC with medium containing 100 µM of MCB. The 
medium was then removed and replaced with HBSS containing 5.6mM glucose and 
incubated at 37oC. (A) Bimane-GS exported into the incubation buffer and (B) 
intracellular bimane-GS were measured over a 15-min time course. The percent efflux 
was calculated by taking the ratio of the amount of bimane-GS in the incubation 
buffer to that of the total bimane-GS (sum of bimane-GS in incubation buffer and cell 
lysate) and multiplying by 100%. Percent efflux at each time point is shown in (C). 
The solid line shows the values from MRP4/Hep G2 cells and the broken line shows 
the values from v/Hep G2 cells. All points for MRP4/ Hep G2 cells with the exception 
of that at 0 min were significantly different from that observed for v/Hep G2 cells 
(Student’s t-test, p<0.05). Values shown are means + SD of two independent 


















































































































4.1.3.   Effect of CCCP on bimane-GS efflux 
Uncouplers of oxidative phosphorylation including CCCP had been shown to inhibit 
the active transport of bimane-GS (Zhang et al., 1996). In this study, the effect of 
CCCP on the efflux of bimane-GS was also examined. The presence of CCCP led to a 
decrease of between 10-27% in total bimane-GS at 5 and 10 minutes (Figure 4.2A). 
Significant decreases in bimane-GS export from both MRP4/Hep G2 and v/Hep G2 
cells (Figure 4.2B) were observed together with corresponding increases in cellular 
accumulation (Figure 4.2C). At the 10-min time point, the presence of CCCP 
abolished MRP4 mediated efflux resulting in similar levels of efflux in both 
MRP4/Hep G2 cells and v/Hep G2 cells. Cell viability as determined by trypan blue 
staining was not affected in all the above experiments. 
 
Figue 4.2. Effect of CCCP at different concentration on bimane-GS efflux  
Cells were preincubated at 10oC with medium containing 100 µM of MCB. The 
medium was then removed and replaced with HBSS containing 5.6mM glucose and 
2.5µM CCCP and incubated at 37oC. Total bimane-GS synthesized (A), the percent 
efflux (B) and the percent cellular accumulation (C) in the absence or in the presence 
of CCCP at 5min and 10 mins are shown. Percent efflux was calculated by taking the 
ratio of the amount of bimane-GS in the incubation buffer to that of the total bimane-
GS (sum of bimane-GS in incubation buffer and cell lysate) and multiplying by 100%. 
The open bars show the values in the absence of CCCP for v/Hep G2cells, the black 
bars show the values in the presence of CCCP for v/Hep G2 cells, the striped bars 
show the values in the absence of CCCP for MRP4/Hep G2 cells and the dotted bars 
show the values in the presence of CCCP for MRP4/Hep G2 cells. Values shown are 
means + SD of three independent determinations. * indicates p<0.05 (Student’s t-test) 














































































4.1.4. Effects of CDNB on bimane-GS export 
The efflux of bimane-GS was also examined in the presence of CDNB. Like MCB, 
CDNB can diffuse freely into cells where it is conjugated with GSH to form  
2,4-dinitrophenyl-glutathione (DNP-GS), a classical substrate for the glutathione-S-
conjugate export pump (Oude Elferink et al., 1993). The conjugation process is 
catalyzed by glutathione-S-transferases. In the presence of 2.5-25µM CDNB, both cell 
lines showed similar decreases in the synthesis of bimane-GS. At 25µM CDNB, the 
decrease was 18%.  Significant decreases in efflux were also observed in both cell 
lines and the decrease was dependent on the concentration of CDNB. Efflux mediated 
by MRP4 was inhibited by 2.5-25µM CDNB. At 5µM and 25µM of CDNB, the 
inhibition observed was >50% and >70% respectively (Table 4.2). Cell viability as 















Table 4.2. Effect of CDNB on bimane-GS efflux 
Cells were incubated in 1 ml DMEM containing 100 µM MCB at 10°C for 60 min 
together with CDNB. The medium was then removed and efflux was carried out at 
37°C in HBSS buffer containing 5.6mM glucose for 10 mins. The difference between 
the efflux from MRP4/HepG2 and those from v/HepG2 cells represents the efflux 
mediated by MRP4. Values shown are expressed as means + SD from three 
independent determinations. *Compared with the corresponding untreated cells, 






































38.7 + 1.1 / 
39.4 + 0.6 
 
 
15.3 + 1.1 
 
28.2 + 0.7 
 
12.9 + 1.5 
1.5 38.0 + 1.4 / 
38.4 + 1.5 
 
12.3 + 0.9* 25.1 + 0.8* 12.8 + 1.7 
2.5 35.6 + 1.1* /  
36.4 + 0.4* 
 
9.7 + 0.7* 18.3 + 0.6* 8.6 + 0.6* 
5 34.9 + 0.3* /  
35.5 + 0.2* 
 
6.3 + 0.5* 12.1 + 0.3* 5.8 + 0.4* 
25 32.2 + 0.6* /  
32.3 + 0.6* 
 










4.1.5. Inhibition of bimane-GS efflux 
MRP4 mediates resistance to purine analogs such as 9-(2-phosphonylmethoxyethyl)-
adenosine and 6-thioguanine (6-TG) (Chen et al., 2001, 2002; Lai et al., 2002; 
Schuetz et al., 1999). MRP4 is also a component of the methotrexate efflux system 
(Chen et al., 2002). Thus, the effects of 6-TG and methotrexate on bimane-GS export 
in MRP4/Hep G2 cells were also examined. At 100 µM, both compounds inhibited 
bimane-GS efflux from MRP4/Hep G2 cells significantly (Table 4.3) without 
affecting efflux from similarly treated v/Hep G2 cells. Efflux from v/Hep G2 cells 
ranged from 13.4 + 1.0 to 13.9 + 1.6 pmol/mg protein.  
 
Several inhibitors including benzbromarone, a uricosuric agent which inhibits DNP-
GS export by MRP5, verapamil and indomethacin are known to block transport 
mediated by MRP proteins (Wijnholds et al., 2000; McAleer et al., 1999; Chen et al., 
2002) and these were tested on MRP4 overexpressing cells. The presence of 
benzbromarone, verapamil and indomethacin all resulted in varying degree of 
inhibition (Table 4.3). To ensure that the inhibition observed was not due to effects on 
transporters that are endogenously expressed in Hep G2 cells, the concentrations of 
inhibitors used in this study were the highest tested without significantly effects on 
the export from similarly treated v/Hep G2 cells (which ranged from 12.6 + 0.2 to 
13.6 + 1.4 pmol/mg protein). The best inhibitory effect was observed with 5 µM of 
benzbromarone. Cell viability as determined by trypan blue staining was not affected 
in all the inhibition experiments.  
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Bimane-GS efflux assay was also carried out in the presence of cyclosporin A, an 
immunosuppressive drug used against autoimmune reaction during organ-transplant 
rejection. Similar inhibition as that to the above inhibitors was observed (Table 4.3). 
 
 
Table 4.3. Effect of Inhibitors on MRP4-mediated export of bimane-GS.  
Cells were incubated in 1 ml DMEM containing 100 µM MCB at 10°C for 60 mins 
together with the inhibitor. The medium was then removed and efflux was carried out 
in HBSS/5.6mM glucose buffer containing the inhibitors at 37oC for 10 mins. The 
difference between the efflux from MRP4/HepG2 and those from v/HepG2 cells 
represents the MRP4 mediated efflux. The 100% value represents MRP4 mediated 
efflux in the absence of an inhibitor. Bimane-GS efflux in v/HepG2 was not affected 
by the presence of the inhibitors and the efflux ranged from 12.6 + 0.2 to 13.9 + 1.6 
nmol/mg protein in this series of assays. Results are expressed as means + SD from at 
least four independent determinations. *Compared with export in the absence of an 
inhibitor, p<0.05, ANOVA analysis. 
 
Inhibitor Percent of control 
 
None  100 
 
100µM methotrexate 53 + 15* 
 
100µM 6-TG 56 + 9* 
 
100µM cyclosporin A 
 




60 + 14* 
25uM verapamil 
 
64 + 4* 









4.2. Cloning and expression of mutant MRP4 
4.2.1.  PCR 
MRP4 cDNA fragments containing mutant sites were obtained by PCR using the full-
length MRP4 cDNA in pcDNA6 vector as the template. Primers used were based on 
the published MRP4 sequence (GenBank access number AF071202). In the first 
round PCR, ten MRP4 fragments, of which every two fragments containing the same 
overlapping mutant nucleotides, were generated as the templates for five mutant 
clones (Figure 4.3). Five mutant MRP4 fragments were then amplified during the 












Figure 4.3.  Template for mutant MRP4 fragments. Lanes 1 and 2 showed 
fragments (size 300bp and 900bp) as the template for clone E103D (original amino 
acid E mutated to D). Similarly, lanes 3 and 4 for E103N; lane 5 and 6 for R362L 
(size 1100bp and 1300bp); lane 7 and 8 for W995F (size 600bp and 1000bp); lane 9 
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Figure 4.4.  Mutant MRP4 fragments. Lanes 1-3 showed fragments, with size at 
1184 bp, for E103D, E103N and R362L clone. Lanes 4-5 show fragments, with size at 




4.2.2. Cloning of mutant MRP4 into cloning vector 
For clones E103D, E103N and R362L, the second round PCR products were cloned 
into pGEM-T vector, and digested with the appropriate restriction enzymes (Figure 
4.5). Clones containing the 1.2-kb EcoRI/EcoRV fragments were then confirmed by 
sequencing. Comparison of the sequence with the wild-type MRP4 using BLAST 
program showed that the sequences of all mutant clones were identical with the only 
exception of mutant nucleotides. 
 
For clone W995F and W995C, the PCR fragments were first cloned into pGEM-T 
vector. After confirming the sequences and mutations by restriction enzyme digestion 
and sequencing, the 1.6-kb HincII/XhoI fragments were subcloned back into 
MRP4/pBS (full-length MRP4 cDNA with no stop codon in pBlueScript vector). 
These were subjected to restriction enzyme digestion and sequencing once again. 
Figure 4.6 shows the electrophoresis results of the digested constructs.  
 






















Figure 4.5.  Restriction enzyme digestion of E103D, E103N and R362L clones by 
EcoRI and EcoR in pGEM-T vector. (A) Lane 1 showed E103D fragment (1184bp) in 
pGEM-T vector (3.0 kb). Similarly, lane 2 showed E103N fragment and (B) lane 1-2 











Figure 4.6.  Restriction enzyme digestion of W995F and W995C clones by HincII 
and XhoI. (A) Lane 1 and 2 showed W995F and W995C fragment (1605bp) in 
pGEM-T vector (3.0kb). (B) Lane 1 and 2 showed the same mutant MRP4 fragments 

































4.2.3. Construction of mutant full-length MRP4 plasmid 
The 1.2-kb EcoRI/EcoRV fragments (for clones E103D, E103N and R362L) and the 
2.8-kb EcoRV/XhoI fragments (for clones W995F and W995C) were subcloned in 
frame back to MRP4/pcDNA6 construct to generate the recombinant vector pcDNA6-
mutant MRP4. The full-length mutant MRP4 fragments in the constructs were 
subjected to restriction enzyme digestion (Figure 4.7) and sequenced again (Figure 













Figure 4.7.  Restriction enzyme digestion of pCDNA6-mutant MRP4 vector by 
EcoR I and Xho I. Lane 1-5 showed the mutant clone E103D, E103N, R362L, W995F 
and W995C accordingly. The 3975 bp bands were mutant MRP4, and the 5.1 kb 
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Figure 4.8.  DNA sequence results of mutant pcDNA6-MRP4. A-E show 
nucleotides sequence blast results of clone E103N, E103D, R362L, W995C and 
W995F (“query” line) accordingly with published MRP4 cDNA sequence (GenBank 
access number AF071202) (“sbjct” line). The sequence of mutated nucleotides (is in 

























Query: 316 acaagagcaatcataaagtgttactggaaatcttatttagttttgggaatttttacgtta 375 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 241 acaagagcaatcataaagtgttactggaaatcttatttagttttgggaatttttacgtta 300 
 
                                                                        
Query: 376 attgagAACagtgccaaagtaatccagcccatatttttgggaaaaattattaattacttt 435 
           |||||| | ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 301 attgagGAAagtgccaaagtaatccagcccatatttttgggaaaaattattaattacttt 360 
 
                                                                        
Query: 436 gaaaattatgatcccatggattctgtggctttgaacacagcgtacgcctatgccacggtg 495 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 361 gaaaattatgatcccatggattctgtggctttgaacacagcgtacgcctatgccacggtg 420 
A
Query: 316 acaagagcaatcataaagtgttactggaaatcttatttagttttgggaatttttacgtta 375 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 241 acaagagcaatcataaagtgttactggaaatcttatttagttttgggaatttttacgtta 300 
 
                                                                        
Query: 376 attgagGACagtgccaaagtaatccagcccatatttttgggaaaaattattaattacttt 435 
           |||||| | ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 301 attgagGAAagtgccaaagtaatccagcccatatttttgggaaaaattattaattacttt 360 
 
                                                                        
Query: 436 gaaaattatgatcccatggattctgtggctttgaacacagcgtacgcctatgccacggtg 495 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






























Query: 122  tgcgctgtgatatctcatcaagtagcaaaaaggtctggattcttcggatgctgacgattg 181 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1195 tgcgctgtgatatctcatcaagtagcaaaaaggtctggattcttcggatgctgacgattg 1136 
 
                                                                         
Query: 182  cctctgacaccctctcaatggctgaggggaagaagagggtaaccgtcagCAGcacagccc 241 
            |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct: 1135 cctctgacaccctctcaatggctgaggggaagaagagggtaaccgtcagCCGcacagccc 1076 
 
                                                                         
Query: 242  catacagcgtcactgccacgaacacgcggctggctgtgatcacactgccgaggagcacgt 301 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 1075 catacagcgtcactgccacgaacacgcggctggctgtgatcacactgccgaggagcacgt 1016 
 
Query: 422  ttgtcatcatcgttgcctttgggtccctgattctggcaaaaactctggatgccgggcagg 481 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2876 ttgtcatcatcgttgcctttgggtccctgattctggcaaaaactctggatgccgggcagg 2935 
 
                                                                         
Query: 482  ttggtttggcactgtcctatgccctcacgctcatggggatgtttcagTGTtgtgttcgac 541 
            ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct: 2936 ttggtttggcactgtcctatgccctcacgctcatggggatgtttcagTGGtgtgttcgac 2995 
 
                                                                         
Query: 542  aaagtgctgaagttgagaatatgatgatctcagtagaaagggtcattgaatacacagacc 601 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2996 aaagtgctgaagttgagaatatgatgatctcagtagaaagggtcattgaatacacagacc 3055 
 
Query: 422  ttgtcatcatcgttgcctttgggtccctgattctggcaaaaactctggatgccgggcagg 481 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 2876 ttgtcatcatcgttgcctttgggtccctgattctggcaaaaactctggatgccgggcagg 2935 
 
                                                                         
Query: 482  ttggtttggcactgtcctatgccctcacgctcatggggatgtttcagTTCtgtgttcgac 541 
            ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct: 2936 ttggtttggcactgtcctatgccctcacgctcatggggatgtttcagTGGtgtgttcgac 2995 
 
                                                                         
Query: 542  aaagtgctgaagttgagaatatgatgatctcagtagaaagggtcattgaatacacagacc 601 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






4.2.4. Expression of MRP4 mutants in HepG2 cells 
Plasmid constructs carrying certain mutant amino acids were stably transfected into 
Hep G2 cells followed by selection with blasticidin. Control blasticidin transfections 
with the wild-type MRP4 and the empty parental vector, pcDNA6T were also 
obtained. Protein expression level was first analyzed using immunoblotting. MRP4 
was cloned in frame with a V5 epitope and a polyhistidine sequence at the C-terminal. 
The predicted size of MRP4 is ~149kD while that with the V5 and polyhistidine 
sequence is ~153kD. Using an anti-V5 antibody, a protein of about 150kD was 
detected in both mutant and wild-type MRP4/ HepG2 (Figure 4.9) but not in v/ 
HepG2. To normalize the protein quantity per experiment, actin expression was also 
detected by the anti-actin antibody. All cell lines showed the expression of 42kD 
actin. Relatively levels of protein expression were estimated by densitometric analysis 
and the ratio of wild-type and mutant MRP4 was calculated. The mutant clones with 
the comparable expression level with wild-type MRP4 were selected for further 
experimentation. 
4.2.5. Localization of mutant MRP4 in HepG2 cells 
Immunostaining was performed to ensure that mutant MRP4 proteins were correctly 
localized to the membrane of the cells. The primary antibody specifically for MRP4 
protein and the secondary antibody conjugated to FITC were used to stain the cells. 
Propidium iodide was used to counterstain the cells to show the nucleic acids. As 






Figure 4.9. Western blot analysis of wild-type and mutant MRP expression in 
HepG2 cells. The numbers in the table below the blots referred to the relative 
expression level. (A) shows the E103D and the E103N clones, (B) the W995F and the 
R362L clones and (C) the W995C clone. Wild-type MRP4 and empty pcDNA6 vector 








Lane 1 2 3 4 5 6 7 8 9 
Name Wild type E103D E103N V 
Ratio 
(MRP4/Actin) 
0.47 0.46 0.65 0.77 0.78 0.74 0.84 0.48 --- 
Ratio 
(Mutant/wild-type) 
1.00 0.99 1.39 1.65 1.67 1.59 1.80 1.04 --- 
Clone selected for 
further analysis 








Lane 1 2 3 4 5 
Name WT V W995F R362L 
Ratio 
(MRP4/Actin) 
1.05 --- 0.93 0.29 0.86 
Ratio 
(Mutant/wild-type) 
1.00 --- 0.88 0.27 0.82 
Clone selected for 
further analysis 
  √  √ 
 
A      1         2         3        4        5       6       7        8        9 
Actin
MRP4










Lane 1 2 3 4 
Name W995C V WT 
Ratio 
(MRP4/Actin) 
0.86 0.62 --- 0.65 
Ratio 
(Mutant/wild-type) 
1.33 0.96 --- 1.00 
Clone selected for 
further analysis 



































Figure 4.10. Immunostaining of Hep G2 cells overexpressing wild-type and mutant  
MRP4. MRP4 was detected by immunofluorescence with MRP4 antibody (green  
signal) and nucleic acids were counterstained with propidium iodide (red signal). Both  











































































































4.3. Functional study of mutant MRP4 
To gain insight into the role of specific highly conserved amino acids of MRP4 on its 
transport activity, site-direct mutageneis was carried on two groups of amino acid. To 
confirm the importance of charged amino acid, Glu103 was substituted with either the 
conservative charged Asp (E103D-MRP4) or the non-conservative uncharged Asn 
(E103N-MRP4), and Arg362 was substituted with the non-conservative uncharged Leu 
(R362L-MRP4). To determine the role of specific highly conserved aromatic amino 
acid on MRP4 transport capacity, two different amino acids were introduced in place 
of Trp995. These included substitution with a non-conservative non-aromatic amino 
acid Cys (W995C-MRP4) as well as a conservative aromatic amino acid Phe (W995-
MRP4). As shown in Figure 4.10, the levels of expression of these mutant proteins 
were comparable or a little higher than those of wild-type MRP4. 
 
4.3.1. Cytotoxic assay 
To examine the drug resistance of mutant MRP4 protein, cytotoxic assay was carried 
out on stable transfected mutant MRP4/HepG2 cells. Wild-type MRP4 and empty 
pcDNA6 vector were used as the positive and negative control respectively. In this 
study, we found that the IC50 values of mutant clones E103N, E103D and R362L for 
both drug 6-TG and dFdC were similar to that of vector. This indicates that 
substitution of charged amino acid at position 103 and 362 in the putative first 
transmembrane segment of MRP4 protein with either conserved or non-conserved 
amino acid residues resulted in the lost of drug resistance for some purine analogues. 
In addition, IC50 value of W995C clone (tryptophan at position 995 in the putative 
second transmembrane segment of MRP4 was changed to non-conserved cystine) 
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decreased dramatically the resistance levels to that of empty vector cells while IC50 
value of W995F clone (tryptophan at position 995 was substituted with conserved 
phenylalanine) was comparable with that of wild-type MRP4 cells. This indicated that 
drug resistance ability of W995C clone was lost while that of the W995F clone 
remained. The IC50 values are shown in Table 4.4. 
 
 
Table 4.4.  IC50 of resistance to drugs of mutant MRP4/HepG2 cells.  
The cells were exposed to dFdC for 72 hours or to 6-TG for 48 hours. MTS reagent 
was added and cells were incubated for 60 minutes. The absorbance at 490 nm was 
measure. IC50 is the concentration at which cell growth is inhibited by 50%. At least 
five drug concentrations were used to determine IC50 values. Each concentration was 
carried out in triplicate. The fold resistance is obtained by the ratio of IC50 of mutant 
or wild-type MRP4 cells to that of control vector cells. 
 
Cell Line  
WT-
MRP4 































































4.3.2. Export of bimane-GS 
A time course of bimane-GS efflux was performed in mutant cells as described in 
section 4.1.2. Control cell lines with the wild-type construct and the empty pcDNA6 
vector were carried out at the same time. As shown in Table 4.5, in all clones, the 
amount of bimane-GS synthesized was similar to that of wild-type MRP4 and vector 
control. However, analysis of bimane-GS transport by all three clones with mutant 
sites at charged amino acid showed that bimane-GS efflux was dramatically reduced 
and was similar to that of the vector-transfected clones (Figure 4.11 A-C). These 
results indicate that substitution of Glu103 with either conservative charged Asp or 
non-conservative uncharged Asn and substitution of Arg362 with non-conservative 
uncharged Leu completely abolished the transport capacities of MRP4 for this 
substrate. Similar results were observed for the two Trp-mutated clones. It was shown 
that non-conservative W995C-MRP4 did not transport bimane-GS and that 
conservative W995F-MRP4 retained part of transport activity, but at a significant 












Table 4.5.  Bimane-GS synthesis of wild-type and mutant MRP4 over a 15-min 
time course. Cells were preincubated at 10oC with medium containing 100 µM of 
MCB. The medium was then removed and replaced with HBSS containing 5.6mM 
glucose and incubated at 37oC. Bimane-GS exported into the incubation buffer and 
intracellular bimane-GS were measured at different time points and added to give the 
total bimane-GS synthesis (sum of bimane-GS in incubation buffer and cell lysate). 
Results are expressed as means + SD of triplicate determinations in a single 
experiment. Similar results were found in a second independent experiment. All 
results for mutant MRP4 cells were comparable to that observed for wild-type MRP4 
and vector cells (Anova analysis, p>0.05).  
 
Cell line Bimane-GS synthesis (nmol/mg protein/15min) 
Wild-type MRP4 
 24.5 + 0.6 
Vector  
 24.3 + 0.4 
E103D-MRP4 
 24.7 +0.6 
E103N-MRP4 
 24.6 + 0.5 
R362L-MRP4 
 24.0 +0.6 
W995F-MRP4 
 23.8 +0.2 
W995C-MRP4 
 23.8 +0.1 
  












Figure 4.11.  Efflux of bimane-glutathione from wild-type and mutant MRP4 
overexpressing Hep G2 cells over a 15-min time course.  
Cells were preincubated with 100 µM of MCB. Bimane-GS exported into the 
incubation buffer and intracellular bimane-GS were measured over a 15-min time 
course. The percent efflux was calculated by taking the ratio of the amount of bimane-
GS in the incubation buffer to that of the total bimane-GS (sum of bimane-GS in 
incubation buffer and cell lysate) and multiplying by 100%. Percent efflux from 
mutant MRP4 clones [A. E103N(▲), B. E103D(shadow▲), C. R362L(♦), D.  
W995C(■), and E. W995F(shadow■)] are shown respectively in figure A-E. Wild-
type MRP4(•) and empty vector(o) control are included  in every figure. All points for 
wild-type MRP4/ Hep G2 cells with the exception of that at 0 min were significantly 
different from that observed for mutant MRP4/Hep G2 and v/Hep G2 cells (Student’s 
t-test, p<0.05). Results are expressed as means + SD of triplicate determinations in a 














































































































































Resistance to nucleotide analogs 
A distinctive character of MRP4 is the ability to confer resistance to a variety of 
nucleotide analogues. These chemotherapeutic reagents include antiretroviral 
compounds, anti-HIV drug PMEA and PMEG; antiviral drug GCV; thiopurine anti-
cancer drugs 6-TG and 6-MP (Schuetz et al. 1999; Lee et al., 2000; Wijnholds et al., 
2000; Adachi et al., 2002). In this study, we demonstrated that cells overexpressing 
MRP4 also showed increase resistance to the anti-cancer nucleoside drug, 
gemcitabine. Gemcitabine is unique among nucleoside drugs because it is active 
against epithelial cancers, including non-small-cell lung, breast, bladder, ovarian and 
head and neck cancers (Allegra and Grem, 1997). It is a pyrimidine analog of 
deoxycytidine that requires functional plasma membrane nucleoside transporter 
proteins to reach its intracellular targets and cause cytotoxicity. It was shown that the 
human concentrative nucleoside transporter (hCNT1) functions as a Na+/nucleoside 
co-transporter and facilitates the update of gemcitabine (Markey et al., 1999). To date, 
there has been no data relating the multi-drug resistant proteins MDR1 or MRP 
proteins to resistance to this agent. 
 
The IC50 value of gemcitabine from MRP4 overexpressing cells is four fold of that 
from control cells indicating that MRP4 may be involved in the transport of 
gemcitabine or its metabolites. Within the cell, gemcitabine is converted to di-/tri-
phosphorylated metabolites. The phosphorylated metabolites of 6-mercaptopurine and 
6-thioguanion are transported by MRP4 (Wielinga et al., 2002). Future work will 
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include the need to determine if gemcitabine or its metabolites or both are transported 
by MRP4. 
 
Transport of glutathione conjugates 
This study was carried out primarily to further characterize the function of MRP4.  
Glutathione-S-conjugates are well-established substrates of MRP1 and MRP2 
(Jedlitschky et al., 1994, 1996; Leier et al., 1994; Muller et al., 1994; Keppler et al., 
1997). Earlier studies on MRP4 had provided indications that MRP4 may indeed be 
able to facilitate the transport of conjugated molecules. This includes work showing 
that MRP4 can transport estradiol-17-β-D-glucuronide (Chen et al., 2001; van Aubel 
et al., 2002) and this transport has been shown to be inhibited competitively by 
estradiol 3,17-disulphate and taurolithocholate 3-sulphate (Zelcer et al., 2003). The 
transport of dehydroepiandrosterone 3-sulphate by MRP4 was also recently 
demonstrated (Zelcer et al., 2003). In addition, glucuronide and glutathione 
conjugates can also inhibit MRP4-mediated transport of methotrexate (Chen et al., 
2002; van Aubel et al., 2002).  
 
In this study, MCB was used to determine if cells expressing MRP4 was able to 
facilitate the efflux the fluoresecent conjugate, bimane-GS. This property of MCB has 
been previously used to study the efflux of glutathione-S-conjugate in human 
leukemia HL-60 cells (Ishikawa et al., 1994), colon adenocarcinoma cells (Zhang et 
al., 1996), human erythrocytes (Pulaski et al., 1995), rat hepatocytes (Fermandez-
Checa et al., 1990) and MRP1 knockout embryonic stem cells (Rappa et al., 1997). 
Our results showed that MRP4 is able to facilitate the efflux of bimane-GS. This 
efflux was significantly reduced in the presence of CCCP. This is probably the 
 95
consequence of uncoupling of oxidative phosphorylation leading to a reduction in 
cellular ATP. Uncouplers of oxidative phosphorylation also had similar inhibitory 
effects on the active efflux of bimane-GS from human colon adenocarcinoma cells 
(Zhang et al., 1996).   
 
The MRP4-mediated efflux of bimane-GS was inhibited by CDNB, a compound that 
is conjugated intracellularly to form the glutathione conjugate, DNP-GS. The 
presence of CDNB led to a significant decrease in the export of bimane-GS. This is 
probably due firstly to its effect on the synthesis of bimane-GS. Secondly, it is 
probable that DNP-GS, the glutathione-conjugated metabolite of CDNB, also exerts a 
negative effect on the export of bimane-GS as the reduction in efflux (>70% at 25µM) 
was much greater than the decrease in bimane-GS synthesis (18% at 25µM). The 
inhibitory effects of DNP-GS on the efflux of bimane-GS had been previously 
described (Terlouw et al., 2001; Zhang et al., 1996) and MRP4-mediated transport of 
methotrexate is also inhibited by DNP-GS (Chen et al., 2002). In this study, 
methotrexate, an MRP4 substrate was also shown to inhibit MRP4-mediated export of 
bimane-GS. The presence of 6-TG also led to decreased bimane-GS efflux and this is 
probably due to inhibition by thio-GMP, the monophosphorylated metabolite of 6-TG 
which is transported by MRP4 (Wielinga et al., 2002). 
 
In other earlier studies, either no uptake or low levels of uptake of leukotriene C4 or 
DNP-GS were observed for MRP4 using membrane vesicles (Chen et al., 2001; van 
Aubel et al., 2002). A similar situation exists with MRP5. Cells expressing MRP5 
were able to excrete GSH and DNP-GS (Wijnholds et al., 2000) but no uptake of 
leukotriene C4 or GSH was observed in membrane vesicles (Jedlitschky et al., 2000). 
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The key difference in results appears to be in the experimental design. It is possible 
that MRP4 transports glutathione conjugates with low affinity and the concentration 
of the glutathione-S-conjugates present in intact cells may be significantly higher than 
that used for membrane vesicle study. In addition, the chemical structures of 
leukotriene C4 and bimane-GS are markedly different and this may account for the 
differences in transport. Alternatively, it may also be possible that MRP4 and MRP5 
function differently from MRP1 and MRP2 with respect to transport of glutathione-S-
conjugates and other unidentified factors besides ATP may be necessary for transport 
to occur. If this were indeed the case, little uptake would be observed with membrane 
vesicles. Similar observations have been made for export of GSH by MRP proteins. 
Studies using membrane vesicles from MRP1-overexpressing cells had shown that 
GSH is not a MRP substrate (Muller et al., 1994). However, export of GSH has been 
observed using intact cells (Wijnholds et al., 2000). This has led to the suggestion that 
MRP1 may have a low affinity for GSH or alternatively, MRP1-mediated export of 
GSH occurs only in association with an unidentified endogenous metabolite present in 
intracellular compartment (Rappa et al., 1997). Cells expressing MRP1, MRP2 and 
MRP5 had also been shown to excrete GSH (Wijnholds et al., 2000; Paulusma et al., 
1999) and increased GSH export was also observed in MRP4-transfected cells (Lai 
and Tan, 2002).  
 
Putative roles of MRP4 
MRP4 is distinct from MRP1-3 as it has the unique ability to transport cAMP and 
cGMP (Chen et al., 2001; van Aubel et al., 2002). Cyclic nucleotides are important 
signaling molecules in many biological systems and cellular efflux may represent one 
possible mode of regulating cellular levels. In addition, cyclic nucleotides also play 
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important roles in the extracellular regulation of fluid balance and MRP4 is thought to 
be the putative efflux pump for urinary cyclic nucleotides (van Aubel et al., 2002). 
MRP4 can mediate resistance to nucleotide analogs (Chen et al., 2001; Lai and Tan, 
2002; Schuetz et al., 1999; Lee et al., 2000) and is able to transport phosphorylated 
metabolites of mercaptopurines (Wielinga et al., 2002).  Hence it is possible that 
MRP4 expression can influence the pharmacokinetics of this class of anticancer 
drugs. Prolong treatment with nucleoside-based antiviral agents can lead to cellular 
resistance with an overexpression of MRP4 (Schuetz et al., 1999; Turriziani et al., 
2002). This greatly reduced the efficiency of the nucleoside-based antiviral agent 9-2-
phosphonylmethoxyethyl-adenine (Schuetz et al., 1999 ). MRP4 is also able to 
increase GSH export (Lai and Tan, 2002) and may thus contribute to GSH in the 
extracellular compartment where GSH can act as a scavenger of electrophiles through 
non-enzymatic reduction or it can serve as a source of glutathione precursor to 
neighboring cells. In the brain, release of GSH from astrocytes is essential for the 
supply of GSH precursors to neighboring neurons (Hirrlinger et al., 2002a). MRP1, 
MRP4 and MRP5 are all expressed in astrocytes and may contribute to cellular export 
of GSH for oxidative defense (Hirrlinger et al., 2002a; 2002b). 
 
This study had demonstrated that MRP4 is able to facilitate the transport of the 
glutathione-conjugate, bimane-GS and this transport can be inhibited by common 
organic anion transport inhibitors. However, MRP4 failed to export bulky anions such 
as fluorescein, 5-chloromethylfluorescein or its glutathione conjugate.  Other 
conjugated molecules including DNP-GS, N-acetyl-DNP-cysteine, α-naphthyl-β-D-
glucuronide and p-nitrophenyl-β-D-glucuronide are also possible substrates for MRP4 
(van Aubel et al., 2002). Thus besides the role of transporting cyclic nucleotides, 
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providing antioxidant defenses, and contributing to resistance to nucleotide-based 
therapy, it is possible that MRP4 can contribute to cellular detoxification by 
facilitating the export of conjugated metabolites of both xenobiotics as well as 
endogenous metabolites such as estradiol conjugates, dehydroepiandrosterone 3-
sulphate and taurolithocholate 3-sulphate (Chen et al., 2001; Zelcer et al., 2003). This 
may indeed be true in the prostate where MRP4 is predominantly expressed in 
basolateral membrane of the basal cells of the prostatic glandular epithelium and may 
contribute to the efflux of xenobiotics into the stroma thus protecting the prostatic 
fluid (Lee et al., 2000).  
 
A clearer picture of the actual physiological contribution of MRP4 to each of the 
possible roles outlined above will only emerge when one can determine the organ and 
cell type specific expression of each MRP protein. This will only come about when 
specific antibodies for all the nine MRP proteins become available. 
 
Mutational analysis 
MRP4 was identified as a protein capable of transporting anionic molecules. These 
include metabolites of chemotherapeutic agents, glutathione-conjugated and 
glucuronide-conjugated organic anions, cAMP and methotrexate (Chen et al., 2001; 
Lai et al., 2002). Earlier studies from our group confirmed that the predicted topology 
structure of MRP4 contained two 6-transmembrane-segment regions and 
demonstrated inhibition of transport between structurally diverse substrates (e.g. 
inhibition of bimane-GS efflux by methothexate). As a step toward determining the 
substrate-binding sites of MRP4, site-directed mutagenesis of highly conserved 
residues were carried out. 
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Role of Trp995  
Based on the Alignment of the protein sequences of MRP family, Trp995 predicted to 
be in the last transmembrane segment (TM12) of MRP4 close to the cytoplasmic face 
of the membrane was selected. This tryptophan residue is extremely well conserved 
among MRP (ABCC) subfamily members, including MRP1, -2, -3, and -6 (Figure 
1.4), but not conserved in human P-glycoprotein (MDR1) or other members of the 
ABCB subfamily. The last TM helix in MSD2 (second membrane spanning domain) 
of MRP4 has a highly amphipathic character, with Trp995 and other amino acids with 
hydrogen-bonding side chains densely clustered on one side of the -helix and 
predominantly in the region predicted to be in the inner leaflet of the plasma 
membrane. The extensive hydrogen-bonding capacity of putative last TM may play an 
important role in the substrate-binding and transport properties of these proteins. 
Interestingly, the topologically comparable TM segment in P-glycoprotein (TM12) 
has also been demonstrated to contain key determinants of substrate specificity, but 
TM12 of this ABCB transporter is significantly less amphipathic than that of MRP 
(ABCC) proteins (Hafkemeyer et al., 1998; Zhang X et al., 1995; Loo and Clarke, 
1993). This difference may be relevant to the apparent differences in the substrate 
specificity and transport mechanisms of MRPs and P-glycoprotein.  
 
To examine the transport activity as well as the drug resistance phenotype of the 
W995F and the W995C mutants, stably transfected human Hep G2 cells were 
generated. Our results showed that transport of bimane-GS by the non-conserved 
substitution clone (W995C) could not be detected and was no different from that 
obtained from vector control-transfected cells. The transport activity by conserved 
replacement (W995F) also decreased significantly compared with that from the wild-
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type MRP4 clone. In addition to the loss of bimane-GS transport, the W995C mutant 
expressing cells were no longer resistant to natural product chemotherapeutic agents, 
including 6-TG and gemcitabine, while the drug resistance profiles appeared 
unchanged in the W995F cells. Similar differential effects on the transport and drug 
resistance profiles had been observed following the mutation of the analogous Trp 
residue in MRP1, MRP2 and MRP3 (Table 5.1).  
 





C(cys) 1) Diminish estradiolglucuronide 
E217βG uptake; 
2) No effect on LTC4 transport; 
3) Lose the ability of resistance against 
chemotherapeutic agent Vinca 
alkaloid vincristine. 
MRP1-Trp1246  
F(Phe) 1) Diminish estradiolglucuronide 
E217βG uptake; 
2) No effect on LTC4 transport. 
Ito, et al., 
2001(a) 
C(cys) 1) Diminish estradiolglucuronide 
E217βG uptake; 
2) Diminish LTC4 and MTX uptake. 
MRP2-Trp1254 
F(Phe) 1) No effect on estradiolglucuronide 
E217βG transport; 
2) Diminish LTC4 and MTX uptake. 
Ito, et al., 
2001(b) 
C(cys) 1) Increase estradiolglucuronide E217βG 
uptake; 
2) Diminish LTC4 and MTX uptake; 
3) No effect on bile salt transport. 
MRP3-Trp1242 
F(Phe) 1) Increase estradiolglucuronide E217βG 
transport; 
2) Diminish LTC4 and MTX uptake; 
3) No effect on bile salt transport. 
Oleschuk, 






Taken together, the aromatic amino acid or aromatic interactions at position 995 of 
MRP4 protein may function to either maintain or form part of a substrate-binding 
pocket, and it may interact directly with the metabolites of nucleoside 
chemotherapeutic drugs and glutathione and glucuronide conjugates. Considering the 
functional difference between W995C and W995F clones, the absence of bimane-GS 
transport ability and drug resistance in the cysteine substituted Trp995 MRP4 mutant 
suggests that although cysteine can participate in hydrogen bonding, it is considerably 
smaller than tryptophan and lacks aromaticity. In other words, this result indicates that 
aromatic interactions possesses specific physical and/or chemical properties that are 
essential for recognition and transport of some MRP4 substrates and general 
hydrogen-bonding capability are not sufficient to maintain the architecture of the 
binding site in MRP4. 
 
Whether or not the substrates are taken up from inner or outer leaflet of plama 
membrane by MRP remains largely unknown. It may depend on the physical 
characteristics of the substrate, such as its hydrophobicity, aromaticity, and charge, as 
well as certain aspects of its chemical structure. It has been proposed that substrates 
for MDR (Pgp) are taken up from the inner leaflet of the plasma membrane (Loo et 
al., 1993). Our finding showed that the hydrogen-bonding aromatic amino acid Trp995 
that is located close to the cytosolic face of the protein is a critical determinant for the 
binding and transport of bimane-GS. The fact suggests that this organic anion may be 





Role of Glu103 and Arg362 
Although the bulky aromatic acid residue Trp is regarded as a key determinant of 
substrate specificity of MRP protein (Ito et al., 2001a, 2001b; Koike et al., 2002; 
Oleschuk et al., 2003), highly conserved charged amino acid predicted in or near the 
transmembrane segments of MRP protein were also shown to be responsible for the 
transport activity and drug resistance of MRPs (Ito et al., 2001c; Haimeur et al., 
2002). For instance, among the MRP proteins, MRP4-Glu103 is the most conserved 
charged residue that is located on TM1 of the first membrane spanning domain. The 
functional importance of this acidic residue may also be conserved, since the 
conserved analogous Asp103 in rat Mrp2 and human MRP1 (Asp325 and Asp336 
respectively) has been demonstrated to be important for transport of the glutathione 
conjugated substrates, DNP-SG and LTC4, and, to a lesser extent, E217βG and other 
conjugated organic anions. Interestingly, a missense mutation of the analogous acidic 
residue in CFTR, E92K, has been associated with a benign cystic fibrosis phenotype 
(Chillon et al., 1993). In the present study, we observed that charged amino acid 
residues Glu103 and Arg362 predicted to be present in TM1 and TM6 respectively of 
the first membrane spanning domain of MRP4 are indeed involved in the transport 
function. The substitution of Glu103 and Arg362 with either non-conserved non-charged 
or conserved charged amino acid residue resulted in the loss of the transport of 
bimane-GS as well as the resistance to 6-thiogunion and gemcitabine. The fact 
suggests that these two residues play a global and essential structural role in 
assembling or maintaining MRP4 in a transport state. Thus, Glu103 and Arg362 are of 
great importance for the function of MRP4.  
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The exact roles of Glu103 and Arg362 (TM1 and TM6 respectively) in the mechanism 
of substrate binding and translocation by MRP4 are unknown. The result that Leu 
could not compensate for the function of Arg at 362 may be accounted for by the 
hypothesis that the cationic side chain of Arg may interact directly with the anionic 
charge of glutathione conjugates and the phosphorylated nucleotide substrates. 
Alternatively, it is also probable that these cationic and anionic amino acids (Glu103 
and Arg362) are necessary parts of the functional structure for substrate recognition 
and transport. Thus mutations in these residues may cause a shift in TM helix packing 
that makes the specific substrates binding site and/or translocation pathway less 
accessible to these substrates.  
 
On the other hand, there are also numerous examples of proteins where side chains of 
charged amino acids are known to form ion pairs interaction between TM helices or 
salt bridges with oppositely charged amino acids and thus provide protein stability 
and/or promote interactions with ligands. For instance, previously study has 
demonstrated that the salt bridge between Lys in TM2 and Asp in TM11 of the 
vesicular monoamine transporter is important for transport activity, and substitution of 
either Lys or Asp by Ala resulted in the disruption of salt bridge between oppositely 
charged amino acids resulting in the loss of transport activity for monoamines 
(Merickel et al., 1997). It is thus highly likely that focused charged residues Glu103 
and Arg362 may make up a salt bridge between TM1 and TM6 or form additional ion 
pairs and/or hydrogen bonds with neighboring polar or charged amino acids in other 
TM helices of MRP4 to contribute to the recognition of glutathione conjugates and 
nucleotide analogues.  
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In addition, the introduction of salt bridges at the x and x + 4 positions in short 
peptides and on protein surfaces can facilitate -helix formation (Popot and 
Engelman, 2000). It has been shown that the same mechanism may hold true for 
human MRP1 and rat Mrp2 (Ito et al., 2001c; Haimeur et al., 2002). Mutagenesis at 
Asp329 and Lys325 of rat MRP2 as well as Lys332 and Asp336 of human MRP1 in the 
same transmembrane helices (TM6) caused a selective loss or reduction of transport 
of various substrates. Two opposite-charged amino acids Lys and Asp in the two 
proteins are located just four amino acids apart and thus could potentially form an 
intrahelical stabilizing salt bridge with one another. Similarly, the focused Glu103 in 
the analogous transmembrane segment of MRP4 may be helpful to form salt bridge 
between Glu102 and cationic Lys106, and therefore contribute to the recognition of 
specific substrates. The mechanism can only be verified when mutations of these two 










Using cells stably overexpressing MRP4, this study provided experimental evidence 
that MRP4, as one of the ABC transporter, can indeed facilitate the ATP-dependent 
efflux of the glutathione conjugate, bimane-glutathione. The transport of bimane-
glutathione can be inhibited by chlorodinitrobenzene. The efflux was also modulated 
by other MRP4 substrates including methotrexate as well as by compounds known to 
inhibit MRP transporters.  
 
This study also confirmed that MRP4 is able to confer resistance to nucleoside 
analogs 6-TG and furthermore extended the drug resistance profile of MRP4 to the 
anti-cancer pyrimidine agent gemcitabine. Nucleoside analogs are an important class 
of chemotherapeutic agents and gemcitabine is unique among them for its activity 
against epithelial cancers. However, to date, the potential contribution of MRP4 as 
well as other MRPs to clinical resistance to nucleoside analogs is not well 
investigated. It remains to be determined if tumors exhibiting drug resistance to 
nucleoside analogs overexpress MRP4. 
 
In addition, our data demonstrated that aromatic amino acid residue Trp1246 predicted 
in the last TM of MSD2 as well as charged amino acids Glu103, Arg362 in TM1 and 
TM6 respectively of MSD1 of MRP4 protein are critical determinant for substrate 
specificity of MRP4-mediated transport and drug resistance. However, due to the 
limited mutated residues, it is difficult to determine structural/functional mechanism 
of the MRP4-mediated transport and drug resistance. It will be of interest to determine 
whether the analogous tryptophan residue in other transmembrane helixes of MRP4 is 
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also important for their transport functions. Other charged residues within MRP4 can 
also be investigated to determine their participation, if any, in the substrate specificity 
















































Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley RM, Tatum A, 
Ziegelmeier MZ, Wezeman M, Matherly LH, Drake RR, Schuetz JD. Expression 
of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. 
(2002) J Biol Chem 277: 38998-39004. 
 
Allegra CJ, Grem JL. Antimetabolites. In: De-Vita VT Jr, editor. Cancer; 
principles and practice of oncology. Philadelphia (PA): Lippin-cott-Raven; 1997. 
p. 490-8. 
 
Athkmets, R., Gerrard, B., Hunchinson, A., and Dean, M., Charecterization of the 
human ABC superfamily: isolation and mapping of 21 new genes using the 
expressed sequence tags database, 1996, Human Mole. Genetics, 5 No.10, 1649-
1655. 
 
Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van 
Deemter L, Borst P, Varadi A, et al. (1998) Functional multidrug resistance 
protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem  273: 
32167-32175 
 
Banoglu, E., Current status of the cytosolic sulfotransferases in the metabolic 
activation of promutagens and procarcinogens, 2000, Curr. Drug. Metab. 1, 1-30. 
 
Belinsky, M.G., Bain, L.J., Balsara, B.B., Testa, J.R. and Kruh, G.D. 
Characterisation of MOAT-C and MOAT-D, new members of the MRP/cMOAT 
subfamily of transporter proteins. 1998, J. Natl. Cancer Inst. 90, 1735-41. 
 
Belinsky, M.G., and Kruh, G.D., MOAT-E (ARA) is a full-length MRP/cMOAT 
subfamily transporter expressed in kedney and liver, 1999, British J. of Cancer, 
80(9), 1342-1349. 
 
Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the 
drug resistance and transport properties of multidrug resistance protein 6 (MRP6, 
ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. 
 
Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart 
J, Kool M, van Soest S, Baas F, et al., 2000, Mutations in ABCC6 cause 
pseudoxanthoma elasticum. Nat Genet 25: 228-531. 
  
Borst, P., Evers, R., Kool, M. and Wijnhold, J. The multidrug resistance protein 
family. 1999, Biochim. Biophys. Acta 1461, 347-357. 
 
Borst, P., Evers, R., Kool, M. and Wijnhold, J. A family of drug transporters: the 
multidrug resistance-associated proteins. 2000, J. Natl. Cancer Inst. 92, 1295-
1302. 
 
Bosch, I., Croop., J, P-glycoprotein multidrug resistance and Cancer, 1996 
Biochim. Biophys. Acta. 1288 F37-F54. 
 
 108
Breuninger LM, Gaughan S Paul, K, Chan T Miki, A, Aaronson SA, and Kruh 
GD. Expression of multidrug resistance-associated protein in NIH/3T3 cells 
confers   multidrug resistance associated with increased drug efflux and altered 
intracellular   drug distribution Cancer Res 1995 55: 5342-5347. 
 
Bryan and J. Aguilar-Bryan L., The ABCs of ATP-sensitive potassium channels: 
more pieces of the puzzle. Curr. Opin. Cell Biol. 9 (1997), pp. 553–559. 
 
Buchler, M., Konig, J., Brom, M., Kartenbeck, j., Spring, H., Horie, T., and 
Keppler, D., cDNA cloning of the hepatocyte canalicular isoform of the multidrug 
resistance protein, cMrp, reveals a novel conjugate export pump deficienct in 
hyperbilirubinemic mutant rats, J. Biol. Chem., 1996, 271, 15091-15098. 
 
Chen, Z.S., Lee, K. and Kruh, G.D.  Transport of cyclic nucleotides and estradiol 
17-β-D-glucuronide by multidrug resistance protein 4: Resistance to 6-
mercaptopurine and 6-thioguanine. 2001, J. Biol. Chem, 276(36):33747-54  
 
Chen, Z., Lee, K., Walther, S., Raftogianis, R., Kuwano, M., Zeng, H. and Kruh, 
G. (2002) Analysis of methotrexate and folate transport by multidrug resistance 
protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. 
Cancer Res. 62, 3144-3150 
 
Chen, Z., Hopper-Borge E., Belinsky MG, Shchaveleva I., Kotova E., and Kruh 
GD., 2003, Characterization of the transport properties of Human Mutidrug 
Resistance Protein 7 (MRP7, ABCC10). Mol. Phar. 63: 351-358 
 
Chillon, M., Nunes, V., Dork, T., Tummler, B., Casals, T., and Estivill, X. (1993) 
Hum. Mol. Genet. 2, 79-80 Microsatellite haplotypes for cystic fibrosis: mutation 
frameworks and evolutionary tracers. Hum Mol Genet. 1993 Jul; 2(7):1015-22. 
 
Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., 
Stewart, A., Kurz, E.U., Ducan, A.M.and Deeley, R. Overexpression of a 
transporter gene in a multidrug resistant human lung cancer cell line. 1992, 
Science 258,1650-1654. 
 
      Cole, SP, Sparks, KE, Fraser, K, Loe, DW, Grant, CE, Wilson, GM and Deeley 
RG. Pharmacological characterization of multidrug resistant MRP-transfected 
human tumor cells. Cancer Res 1994 54: 5902-5910 
 
Cole, P.C., Deeley, R.G., Multidrug resistance mediated by the ATP-binding 
cassette transporter protein MRP, 1998, BioEssays, 20, 931-940. 
 
Cole SPC and Deeley RG. Multidrug resistance II: MRP and related proteins. In: 
Encyclopedia of cancer, edited by Bertino JR. San Diego, CA: Elsevier Science, 
2002, p. 255-267.  
 
Cui, Y., Konig, J., Buchholz, J.K., Spring, H., Leier, I. and Keppler, D.  Drug 
resistance and ATP-dependent conjugate transport mediated by the apical 
multidrug resistance protein, MRP2, permanently expressed in human and canine 
cells. Mol. 1999, Pharmacol. 55,929-937. 
 109
Daoud, R., Julien, M., Gros, P., and Georges, E. Major Photoaffinity Drug 
Binding Sites in Multidrug Resistance Protein 1 (MRP1) Are within 
Transmembrane Domains 10-11 and 16-17* (2001) J. Biol. Chem. 276, 12324-
12330 
 
Deeley RG and Cole SP (1997) Function, evolution and structure of multidrug 
resistance protein (MRP). Semin Cancer Biol  8: 193-204 
 
Decottignies, A. and Goffeau, A., Complete inventory of the yeast ABC proteins. 
Nat. Genet. 15 (1997), pp. 137–145. 
 
Fernandez-Checa, J.C. and Kaplowitz, N. (1990) The use of monocholorobimane 
to determine hepatic GSH levels and synthesis. Anal. Biochem. 190, 212-219. 
 
Fojo, A.T., Peng, J.W., Gottesman, M.M., and Pastan, L., Amplification of DNA 
sequences in human multidrug-resistant KB carcinoma cells, 1985,Genetics, 82, 
7661-7665. 
 
Gao M, Yamazaki M, Loe DW, Westlake CJ, Grant CE, Cole SP and Deeley RG 
(1998) Multidrug resistance protein. Identification of regions required for active 
transport of leukotriene C4. J Biol Chem  273: 10733-10740 
 
Glatt, H., Sulfotransferases in the bioactivation of xenobiotics, 2000, Chem. Biol. 
Interact. 129, 141-170. 
 
Guinamard R and Akabas MH (1999) Arg352 is a major determinant of charge 
selectivity in the cystic fibrosis transmembrane conductance regulator chloride 
channel. Biochemistry  38: 5528-5537 
 
Hafkemeyer, P., Dey, S., Ambudkar, S. V., Hrycyna, C. A., Pastan, I., and 
Gottesman, M. M. Contribution to substrate specificity and transport of 
nonconserved residues in transmembrane domain 12 of human P-glycoprotein. 
 (1998) Biochemistry 37, 16400-16409 
 
Haimeur Anass, Roger G. Deeley, and Susan P. C. Cole. Charged Amino Acids in 
the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 
(MRP1/ABCC1) Are Critical Determinants of Transport Activity. (2002) J. Biol. 
Chem., 277, 41326-41333 
 
Higgins. C. F., ABC transporters: from microorganisms to man. Ann. Rev. Cell 
Biol. 8 (1992), pp. 67–113. 
 
Hipfner, D.R., Almquist, K.C., Leslie, E.M., Gerlach, J.H., Grant, C.E., Deeley, 
R.G., and Cole, S.P.C., Membrane topology of the multidrug resistance protein 
(MRP), 1997, J. Biol. Chem., 272, 23623-23630. 
 
Hipfner, D.R., Deeley, R. G. and Cole, S.P., Structural, mechanistic and clinical 
aspects of MRP1, 1999, Biochim. Biophys. Acta 1461, 359-376. 
 
 110
Hirrlinger. J, Schulz, J, Dringen. R, Glutathione release from cultured brain cells: 
multidrug resistance protein 1 mediates the release of GSH from rat astroglial 
cells, J. Neurosci. Res. 69, (2002) 318-326. 
 
Hirrlinger. J, Konig. J, Dringen. R, Expression of mRNAs of multidrug resistance 
proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and 
neurons, J. Neurochem. 82 (2002) 716-719. 
 
Hodgson, E., and Levi, P., Textbook of modern toxicology, Chapter 3, 1997, 
Publisher: Appleton & Lange, 2nd edition. 
 
Hooijberg, J.H., Broxterman, H.J., Kool, M., Assaraf, Y. G., Peters, G.J., 
Noordhuis, P., et al., Antifolate resistance mediated by the multidrug resistance 
proteins MRP1 and MRP2. 1999, Cancer Res. 59, 2532-2535. 
 
Hopper, E., Belinsky, M.G., Zeng, H., Tosolini, A., Testa, J.R. and Kruh, G.D. 
Analysis of the structure and expression pattern of MRP7 (ABCC10), a new 
member of the MRP subfamily, 2001, Cancer Lett. 162, 181-191. 
 
Hyde, S.C., Emsley, P., Hartshorn, M.J., Mimmack, M.M., Gileadi, U., Pearce, 
S.R., Gallagher, M.P., Gill, D.R., Hubbard, R.E. and Higgins, C.F., Structural 
model of ATP-binding proteins associated with cystic fibrosis, multidrug 
resistance and bacterial transport, 1990, Nature 346, 362-365. 
 
Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A. 
Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-
associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 
10;277(19):16860-7. 
 
Ishikawa, T., Wright, C. and Ishizuka, H. (1994) GS-X pump is functionally 
overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia 
HL-60 cells and down-regulated by cell differentiation. J. Biol. Chem. 269, 
29085-29093 
 
Ito, K., Olsen, S. L., Qiu, W., Deeley, R. G., and Cole, S. P. C. Mutation of a 
Single Conserved Tryptophan in Multidrug Resistance Protein 1 (MRP1/ABCC1) 
Results in Loss of Drug Resistance and Selective Loss of Organic Anion 
Transport. (2001a) J. Biol. Chem. 276, 15616-15624 
 
Ito, K., Oleschuk, C. J., Westlake, C., Vasa, M., Deeley, R. G., and Cole, S. P. C. 
Mutation of Try1254 in the Multispecific Organic Anion Transporter, Multidrug 
Resistance Protein 2 (MRP2) (ABCC2), Alters substrate Specificity and Results in 
Loss of Methotrexate Transport Activity. (2001b) J. Biol. Chem. 276, 38108-
38114 
 
Ito Kousei, Hiroshi Suzuki, and Yuichi Sugiyama. Charged Amino Acids in the 
Transmembrane Domains Are Involved in the Determination of the Substrate 
Specificity of Rat Mrp2. (2001c) Mol Pharmacol 59: 1077-1085 
 
 111
Jedlitschky, G., Leier, I., Buchholz, U., Center, M. And Keppler, D. (1994) ATP-
dependent transport of glutathione S-conjugates by the multidrug resistance-
associated protein. Cancer Res. 54, 4833-4836 
 
Jedlitschky, G., Leier, I., Buchholz, U., Barnouim, K., Gerhart, K. and Kepple, D., 
Transport of glutathione, glucuronide and sulfate conjugates by the MRP gene-
encoded conjugate export pump, 1996, Cancer Res. 56, 988-994. 
 
Jedlitschky, G., Burchell, B. and Keppler D. (2000) The multidrug resistance 
protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. 
Biol. Chem. 275, 30069-30074 
 
Kamencic. H, Lyon. A, Paterson. P, Juurlink. B, Monochlorobimane fluorometric 
method to measure tissue glutathione, Anal. Biochem. 286, (2000) 35-37. 
 
Keppler, D., Leier, I. and Jedlitschky, G. (1997) Transport of glutathione 
conjugates and glucuronides by multidrug resistance proteins MRP1 and MRP2. 
Biol. Chem. 378, 787-791 
 
Klein, I., Sarkadi, B. and Varadi, A., An inventory of human ABC proteins. 1999, 
Biochim. Biophys. Acta 1461, 237-262. 
 
Koike Koji, Curtis J. Oleschuk, Anass Haimeur, Sharon L. Olsen, Roger G. 
Deeley, and Susan P.C. Cole. Multiple Membrane-associated Tryptophan 
Residues Contribute to the Transport Activity and Substrate Specificity of the 
Human Multidrug Resistance Protein, MRP1. (2002) J. Biol. Chem. 277, 49495-
49503. 
 
Konig, J., Nies, A., Cui, Y., Leier, I., and Keppler, D., Conjugate export pump of 
the multidrug resistance protein (MRP) family: localiztion, substrate specificity, 
and MRP2-mediated drug resistance. 1999, Biochim. Biophys Acta, 1461,377-
394. 
 
Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J.T., Juijn, J.A., 
Baas, F. and Brost, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 
AND MRP5, homologues of the multidrug reistance-associated protein gene 
(MRP1) in human cancer cell lines. 1997, Cancer Res. 57, 3537-3547. 
 
Kool, M., van der Linden, M., de Haas, M., Scheffer, G.L., de Vree, J.M., Smith, 
A.J., Jansen, G., Peters, G.J., Ponne, N., Scheper, R.J., Oude Eflerink, R.P.J., Baas 
F.  and Borst, P. MRP3, an organic anion transporter able to transport anti-cancer 
drugs. 1999a, Proc. Natl. Acad. Sci. USA 96, 6914-6919. 
 
Kool, M., Linden, M., Haas, M., Baas, F., and Borst, P., Expression of human 
MRP6, and homologue of the mulidrug resistance protein gene MRP1, in tissues 
and cancer cells, 1999b, Cancer Research, 59, 175-182. 
 
Lai, L. and Tan, T. (2002) Role of glutathione in the multidrug resistance protein 
4 (MRP4/ABCC4) mediated efflux of cAMP and resistance to purine analogues. 
Biochem. J. 361, 497-503 
 112
 
Lee, K., Belinsky, M.G., Bell, D.W., Testa, J.R. and Kruh, G.D. Isolation of 
MOAT-B, a widely expressed multidrug reistance-associated protein / canalicular 
multispecific organic anion transporter-related transporter. 1998, Cancer Res. 58, 
2741-2747. 
 
Lee, K., Klein-Szanto, J., Kruh, G., Analysis of the MRP4 drug resistance profile 
in Transfected NIH3T3 cells. 2000, J. Natl. Can. Inst. 92. no.23, 1934-1940. 
 
Lee, T., Hammond, C. and Ballatori, N. (2001) Intracellular glutathione regulates 
taurocholate transport in HepG2 cells. Toxicol. Appl. Pharmacol. 174, 207-215 
 
Leier, I., Jedlitschky, G., Buchholz, U., Cole, S.P., Deeley, R.G. and Keppler, D., 
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and 
structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810. 
 
Leier, I., Jedlitschky, G., Büchler, M., Buchholz, U., Brom, M. and Keppler, D. 
(1996) Identification of the biosynthetic leukotriene C4 export pump in murine 
mastocytoma cells as a homolog of the multidrug-resistance protein. Eur. J. 
Biochem. 242, 201-205 
 
Leslie, E., Deeley, R. and Cole, S. (2001a) Toxicology relevance of the multidrug 
resistance protein 1, MRP1 and related transporters. Toxicology 167, 3-23 
 
Leslie, E.M., Ito, K., Upadhyaya, P., Hecht, S.S., Deeley, R.G. and Cole, S.P.C. 
Transport of the β-O-glucuronide conjugate of the tabacco-specific carcinogen 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance 
protein 1 (MRP1). 2001b, J. Biol. Chem. 276, 27846-27854. 
 
Loe, D. W., Almquist K.C., Deeley R.G. and Cole S.P.C., Multidrug resistance 
protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents 
in membrane vesicles: demonstration of glutathione-dependent vincristine 
transport. J. Biol. Chem. 271 (1996a), pp. 9675–9682. 
 
Loe D.W., K.C. Almquist, S.P.C. Cole and R.G. Deeley , ATP-dependent 17β-
estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein: 
inhibition by cholestatic steroids. J. Biol. Chem. 271 (1996b), pp. 9683–9689. 
 
Loe, D.W., Deeley, R.G., and Cole, S.P.C., Characterization of vincristine 
transport by the Mr 190,000 multidrug resistance protein (MRP): evidence for 
contransport with reduced glutathione, 1998, Cancer Res, 58, 5130-5136. 
 
Loe D.W. , C.J. Oleschuk, R.G. Deeley and S.P.C. Cole , Structure-activity 
studies of verapamil analogs that modulate transport of leukotriene C4 and 
reduced glutathione by multidrug resistance protein MRP1. Biochem. Biophys. 
Res. Commun. 275 (2000), pp. 795–803. 
 
Loo, T. W., and Clarke, D. M. Mutation of glutamate 309 to glutamine alters one 
Ca(2+)-binding site in the Ca(2+)-ATPase of sarcoplasmic reticulum expressed in 
Sf9 cells. (1993) J. Biol. Chem. 268, 19965-19972 
 113
 
Loo TW and Clarke DM (1999) Merck Frosst Award Lecture 1998. Molecular 
dissection of the human multidrug resistance P-glycoprotein. Biochem Cell 
Biol  77: 11-23 
 
Mackey JR, Yao SYM, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young 
JD. Gemcitabine transport in xenopus oocytes expressing recombinant plasma 
membrane mammalian nucleoside transporters. (1999) J. Natl. Cancer Inst. 91: 
1876-81. 
 
McAleer, M., Breen, M., White, N., and Matthews, N., pABC11, a member of the 
ABC family of proteins, has anion transporter activity but does not confer 
multidrug resistance when overexpressed in human embryonic kidney 293 cells. 
1999, J. Biol. Chem., 274, 23541-23548. 
 
Merickel A, Kaback HR and Edwards RH (1997) Charged residues in 
transmembrane domains II and XI of a vesicular monoamine transporter form a 
charge pair that promotes high affinity substrate recognition. J Biol Chem  272: 
5403-5408. 
 
Muller, M., Meijer, C., Zaman, G., Borst, P., Scheper, R., Mulder, N., de Vries, E. 
and Jansen, P. (1994) Overexpression of the gene encoding the multidrug 
resistance-associated protein results in increased ATP-dependent glutathione S-
conjugate transport. Proc. Natl. Acad. Sci. USA 91, 13033-13037 
 
Oleschuk., C. J., Deeley, R. G., and Cole, S. P. C. Substitution of Trp1242 of TM17 
alters substrate specificity of human multidrug resistance protein 3. (2003) Am. 
J. Physiol. 284, G280-G289.  
 
Oude Elferink, R., Bakker, C. and Jansen, P. (1993) Glutathione-conjugate 
transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem. J. 290, 
759-764 
 
Paulusma, C., van Geer, M., Evers, R., Heijn, M., Ottenhoff, R., Borst, P. and 
Ould Elferink, R. (1999) Canalicular multispecific organic anion transporter/ 
multidrug resistance protein 2 mediates low-affinity transport of reduced 
glutatione. Biochem. J. 338, 393-401 
 
Popot, J. L., and Engelman, D. M. Helical membrane protein folding, stability, 
and evolution. (2000) Annu. Rev. Biochem. 69, 881-922 
 
Pulaski, L. and Bartosz, G. (1995) Transport of bimane-S-glutathione in human 
erythrocytes. Biochim. Biophys. Acta 1268, 279-284 
 
Qian Y.-M., W. Qiu, M. Gao, C. J. Westlake, S. P. C. Cole, and R. G. Deeley 
Characterization of Binding of Leukotriene C4 by Human Multidrug Resistance 
Protein 1. Evidence of differential interactions with NH2- and COOH-proximal 
halves of the protein. J. Biol. Chem, October 19, 2001; 276(42): 38636 - 38644. 
 
 114
Rappa, G., Lorico, A., Flavell, R. and Sartorelli, A. (1997) Evidence that the 
multidrug resistance protein (MRP) functions as a co-transporter of glutathione 
and natural product toxins. Cancer Res. 57, 5232-5237 
 
Roelofsen, H., Vos, T., Schippers, I., Kuipers, F., Koning, H., Moshage, H., 
Jansen, P. and Müller, M. (1997) Increased levels of the multidrug resistance 
protein in lateral membranes of proliferating hepatocyte-derived cells. 
Gastroenterology 112, 511-521 
 
Roninson, I.B., Chin, J.E., Choi, K., Gros, P., Housman, D., Fojo, A., Shen D.W., 
Gottesman, M.M., and Pastan, I., Isolation of human mdr DNA sequences 
amplified in multidrug-resistant KB carcinoma cells, 1986, Medical Sciences, 83, 
4538-4542. 
 
Ryu, S., Kawabe, T., Nada, S., and Yamaguchi, A. Identification of basic residues 
involved in drug export function of human multidrug resistance associated protein 
2. (2000) J. Biol. Chem. 275, 39617-39624 
 
Schuetz, J., Connelly, M., Sun, D., Paibir, S., Flynn, P., Srinivas, R., Kumar, A. 
and Fridland, A. (1999) MRP4: A previously unidentified factor in resistance to 
nucleoside-based antiviral drugs. Nature Med. 5, 1048-1051 
 
Seelig, A., Li, Blatter, X., and Wohnsland, F. (2000) Int. J. Clin. Pharmacol. 
Therap. 38, 111-121  
 
Sheppard DN and Welsh MJ (1999) Structure and function of the CFTR chloride 
channel. Physiol Rev  79: S23-S45 
 
Stride BD, Cole SP and Deeley RG (1999) Localization of a substrate specificity 
domain in the multidrug resistance protein. J Biol Chem  274: 22877-22883 
 
St.Pierre M.V., M.E. Serrano, R.I.R. Macias, U. Dubs, M. Hoechli, U. Lauper, 
P.J. Meier and J.J.G. Marin , Expression of members of the multidrug resistance 
protein family in human term placenta. Am. J. Physiol. 279 (2000), pp. R1495–
R1503. 
 
Suzuki T., Nishio, K., Sasaki. H, Kurokawa, H., Saito, F., Ikeuchi, T., Tanabe, S., 
Terada, M., Saijo N., cDNA cloning of a short type of multidrug resistance protein 
homologue, SMRP, from a human lung cancer cell line. 1997, Biochem & 
Biophys, Res. Comm., 238, 790-794. 
 
Suzuki, T., Sasaki, H., Kuh, H., Agui, M., Tatsumi, Y., Tanabe, S., Terada, M., 
Saijo, N., and Nishio, K., Detailed structural analysis on both human MRP5 and 
mouse mrp5 transcripts. 2000, Gene, 242, 167-173.  
 
Tammur, J., Prades, C., Arnould, I., Rzhetsky, A., Hutchinson, A., Adachi, M., 
Schuetz, J., Swoboda, K., Ptacek, L., Rosier, M., Dean, M. and Allikmets, R. 
(2001) Two new genes from the human ATP-binding cassette transporter 
superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. 
Gene 273, 89-96 
 115
 
Terlouw, S., Masereeuw, R., van den Broek, P., Notenboom, S. and Russel, R. 
(2001) Role of multidrug resistance protein 2 (MRP2) in glutathione-bimane 
efflux from Caco-2 and rat renal proximal tubule cells. Brit. J. Pharmacol. 134, 
931-938. 
 
Turriziani. O, Schuetz. J, Focher. F, Scagnolari. C, Sampath. J, Adachi. M, 
Bambacioni. F, Riva. E, Antonelli. G, Impaired 2’,3’-dideoxy-3’-thiacytidine 
accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance 
independent of multidrug resistant protein 4 with a possible role for ATP-binding 
cassette C11, Biochem. J. 368 (2002) 325-332. 
 
van Aubel, R., Smeets, P., Peters, J., Bindels, R. and Russel, F. (2002) The 
MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human 
kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. 
Am. Soc. Nephrol. 13, 595-603. 
 
Welsh M.J. and Smith A.E., Molecular mechanisms of CFTR chloride channel 
dysfunction in cystic fibrosis. Cell. 1993 Jul 2;73(7):1251-4. Review. 
 
Wielinga. P, Reid. G, Challa. E, van der Heijden. I, van Deemter. L, de Hass. M, 
Mol. C, Kuil. A, Groeneveld. E, Schuetz. J, Brouwer. C, de Abreu. R, Wijnholds. 
J, Beijnen. J, Borst. P, Thiopurine metabolism and identification of the thiopurine 
metabolites transported by MRP4 and MRP5 overexpressed in human embryonic 
kidney cells, Mol. Pharmacol. 62, (2002) 1321-1331. 
 
Wijnholds, J., Mol, C., Deemter, L., Haas, M., Scheffer, G., Baas, F., Beijnen, J., 
Scheper, R., Hatse, S., Clercq, E., Balzarini, J., and Borst, P., Multidrug-resistance 
protein 5 is a multispecific organic anion transporter able to transport nucleotide 
analogs, 2000, PNAS, vol. 97, 7476-7481. 
 
Yabuuchi H, Shimizu H, Takayanagi S, Ishikawa T. Multiple splicing variants of 
two new human ATP-binding cassette transporters, ABCC11 and ABCC12. 
Biochem Biophys Res Commun. 2001 Nov 9;288(4):933-9. 
 
Zaman, G. J.R., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., 
Paulusma, C., Elferink, R.P.J., Baas, F. and Borst, P. Role of glutathione in the 
export of compounds from cells by the multidrug-resistance-associated protein. 
1995, Proc. Natl. Acad. Sci. USA 92, 7690-7694. 
 
Zelcer. N, Reid. G, Weilinga. P, Kuil. A, van der Heijden. I, Schuetz. J, Borst. P, 
Steroid and bile acid conjugates are substrates of human multidrug-resistance 
protein (MRP) 4 (ATP-binding cassette C4), Biochem. J. 371, (2003) 361-367. 
 
Zeng Hao, Lisa J. Bain, Martin G. Belinsky, and Gary D. Kruh Expression of 
Multidrug Resistance Protein-3 (Multispecific Organic Anion Transporter-D) in 
Human Embryonic Kidney 293 Cells Confers Resistance to Anticancer Agents  
Cancer Res 1999 59: 5964-5967. 
 
 116
Zeng, H., Liu, G., Rea, P.A. and Kruh, G.D. Transport of amphipathic anion by 
human multidrug resistance protein 3. 2000, Cancer Res. 60, 4779-4784. 
 
Zhang, D., Cole, S. P. C., and Deeley, R. G. Identification of an amino acid 
residue in multidrug resistance protein 1 critical for conferring resistance to 
anthracyclines. (2001a) J. Biol. Chem. 276, 13231-13239 
 
Zhang, D., Cole, S. P. C., and Deeley, R. G. Identification of nonconserved amino 
acid residue in multidrug resistance protein 1 important for determining substrate 
specificity. (2001b) J. Biol. Chem. 276, 34966-34974 
 
Zhang, K., Wong, K.P., Active transport of glutathione S-conjugate in Human 
colon adenocarcinoma cells, 1996, Cancer Letters, 108, 143-151. 
 
Zhang, K., Chew, M., Yang, E.B., Wong, K.P., and Mack, P., Modulation of 
cisplatin cytotoxicity and cisplatin-induced DNA cross-links in hepG2 cells by 
regulation of glutathione-related mechanisms, 2001, Mol Pharmacol, 59, 837-843. 
 
Zhang, X., Collins, K. I., and Greenberger, L. M. Functional Evidence That 
Transmembrane 12 and the Loop between Transmembrane 11 and 12 Form Part 
of the Drug-binding Domain in P-glycoprotein Encoded by MDR1. (1995) J. Biol. 
Chem. 270, 5441-5448. 
 
